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Introduction
Introduction
Renal cell carcinomas (RCCs) are malignant renal tumors that originate from the renal 
cortex and represent the vast majority of primary renal neoplasms (approximately 
85%). Other, less frequent malignant renal tumors are transitional cell carcinomas 
(8%) and nephroblastomas (6%), of which the latter only affects children [1]. From 
the mid-seventies until the nineties, the incidence of RCCs has steadily increased. 
Currently, RCC accounts for approximately 2% of all adult malignancies in the 
Western countries [2]. Approximately 2,200 people are diagnosed with RCC and 950 
people succumb to this disease in the Netherlands each year [3]. The rapid increase 
of this disease in the final quarter of the twentieth century is mainly caused by 
improved detection with conventional radiological techniques such as ultrasound, 
Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), but is also 
associated with the increase of cigarette smoking, obesity, and hypertension [4-6]. 
RCC is not a single entity, but rather a collection of different types of tumors, each 
derived from the various parts of the nephron, the principle element of the kidney. 
They are all characterized by distinct molecular changes,  histological features, and 
clinical phenotypes. The most commonly used pathologic classification is based on 
the morphology, growth pattern, cell of origin, histological, and molecular basis of 
the different types [7]. As depicted in Table 1, the clear cell subtype (ccRCC) is most 
common and accounts for approximately 85% of all RCC cases. ccRCC is known to be 
one of the most aggressive types of RCC and is associated with significantly poorer 
survival rates [8, 9]. Moreover, clinical management of this disease is complicated by 
the fact that this subtype is highly resistant to chemotherapy and radiation [10-13].
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Table 1. Incidence of renal cell carcinomas [1, 7]
RCC subtype Incidence (%)
Clear cell renal cell carcinoma 80-85
Papillary renal cell carcinoma 11
Chromophobe renal cell carcinoma 4
Carcinoma of the collecting ducts of Bellini <1
Renal medulary carcinoma <1
Xp11 translocation carcinomas <1
Carcinoma associated with neuroblastoma <1
Mucinous tubular and spindle cell carcinoma <1
Renal cell carcinoma unclassified <1
Current treatment of ccRCC
The treatment of ccRCC is heavily dependent on disease stage. Surgical resection 
is usually the first choice in case of localized ccRCC. However, approximately 30% 
of patients present with metastatic disease, and recurrence occurs in about 40% 
of patients treated for a localized tumor [14, 15]. Because of the large number of 
patients with advanced disease and the lack of good response to chemotherapy and 
radiotherapy [10, 13] the search for new therapeutic strategies has been ongoing 
since the mid-eighties, resulting in various immunotherapeutic strategies like high 
dose interleukin-2 (IL-2) and interferon-α (INF-α). Unfortunately, these agents have a 
significant toxicity profile and clinical benefit was observed in only very few cases [13, 16]. 
The development of agents targeting the vascular endothelial growth factor 
(VEGF) pathway, tyrosine kinase inhibitors (TKIs) and mammalian target of 
rapamycin inhibitors (mTORs) mark a new era in the treatment of metastatic 
ccRCC in terms of progression-free survival (PFS) [17-25]. The choice for a specific 
agent is often complex and depends on the prognostic score according to the 
Memorial Sloan-Kettering Cancer Center (MSKCC) scoring system, extent of 
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the disease, location of metastases, and any prior treatment. Table 2 provides a 
brief overview of the current first-line therapeutic options of metastatic ccRCC.
Although targeted agents result in clinical benefit in the majority of patients, 
side effects like hypertension, fatigue, nausea, hand-foot skin reactions, and diarrhea 
are frequently seen and can be severe, sometimes even leading to dose reduction. 
In addition, little is known about the long term effects of these agents [26]. Moreover, 
treatment with these agents is chronic and cessation of treatment can lead to 
flare-up of the disease [27]. Finally, because eventually treatment resistance occurs 
in almost all patients, ccRCC remains a largely incurable disease. Because of these 
unmet needs in the treatment of ccRCC, the search for novel systemic treatment 
strategies with less toxicity and significant anti-tumor effect has continued. 
Table 2. Current first-line treatment strategies for metastatic RCC. Adapted from the EAU guidelines on renal 
cell carcinoma [41]
RCC subtype Prognostic group First-line
sunitinib
Good pazopanib
ccRCC or bevacizumab + INF-α
intermediate IL-2
INF-α
Non-clear cell RCC Any No consensus
14
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Tumor-associated antigens 
An alternative therapeutic approach in cancer treatment is to exploit tumor-associated 
antigens (TAAs) expressed by tumor cells. TAAs are present on both malignant cells 
and normal cells, but the expression of these antigens is significantly higher on tumor 
cells. A variety of molecules can be used to target TAAs, such peptides or monoclonal 
antibodies (mAb). By coupling chemotherapeutic agents, toxins or radionuclides to 
these targeting molecules, a cytotoxic load can be guided specifically to the tumor. 
Targeting Carbonic Anhydrase IX with monoclonal antibody G250 
Over the years, several mAbs against TAAs have been defined in RCC [28-33]. Most of 
these mAbs only detect certain subtypes of RCC and show extensive crossreactivity 
with non-tumorous tissues. The murine mAb G250 that recognizes a TAA on RCC 
tumor cells was first described in 1986 [34]. The then named ‘G250-antigen’ was 
later identified as Carbonic Anhydrase isoform IX (CAIX), a protein that plays an 
important role in maintaining the intracellular pH under hypoxic conditions [35, 36]. 
In normoxic conditions, hypoxia-inducible-factor-1α (HIF-1α) binds to the Von Hippel 
Lindau protein (pVHL) and is subsequently rapidly degraded. Reduced oxygen 
availability leads to inhibition of binding of pVHL to HIF-1α, resulting in downstream 
transcription of hypoxia-inducible genes such as VEGF, platelet-derived growth factor 
(PDGF) and Carbonic Anhydrase IX (CAIX). VEGF and PDGF both play an important role 
in angiogenesis, whereas CAIX helps regulating the intra- and extracellular pH and fluid 
balance by catalyzing the reversible reaction CO
2 
+ H
2
O  HCO
3
-
 
+ H+ [35, 36]. In several 
solid tumor types, spatial disorganization and flow-based disruption of an abnormal 
microvasculature is initiated by the growing tumor. These processes lead to hypoxia 
and ultimately to upregulation of hypoxia-inducible genes, including CAIX [37]. 
15
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In ccRCC, hypoxia is mimicked by a molecular defect in one of the key proteins in 
the cascade, namely pVHL. Due to a mutation in the VHL gene and the subsequent 
(functional) loss of pVHL, the binding of this protein to HIF-1α does not occur. Because of 
the constitutive presence of HIF-1α in ccRCC, the downstream hypoxia-inducible genes 
are upregulated, ultimately leading to VEGF, PDGF and CAIX overexpression in these 
tumors. Other types of RCCs (and other carcinomas) demonstrate limited expression 
of CAIX, which can be attributed to local hypoxia [37]. However, ccRCC lesions more 
often and more consistently demonstrate high expression of the antigen [38, 39]. 
CAIX is not found in normal renal tissue nor in benign cysts, whereas high expression 
is reported in up to 94% of the ccRCC cases [39, 40]. Only low levels are expressed 
in other organs, mainly in the upper gastrointestinal tract and the bile ducts [40]. 
In view of the high and specific CAIX expression in ccRCC, it is an excellent TAA that 
can be targeted with mAb G250 for both imaging and treatment of ccRCC lesions. 
Although G250 is not the only antibody that targets CAIX,  it is the most extensively 
investigated one, and the only one that has been used in clinical trials to date. While 
the first clinical studies performed with radiolabeled murine G250 were highly 
promising, the murine antibody provoked human anti-mouse antibodies (HAMA) 
responses in all patients. To circumvent this HAMA-formation, a chimeric (murine/
human) variant of G250 was produced, which was later denominated girentuximab.
16
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Thesis outline
The aim of this thesis was to further optimize the detection and treatment of ccRCC using 
radiolabeled mAb cG250/girentuximab. The preclinical and clinical studies presented 
in this thesis focus on detection of ccRCC with Indium-111 (111In) labeled girentuximab 
and treatment of advanced disease with Lutetium-177 (177Lu)-girentuximab. 
In addition, the feasibility of novel fluorescence imaging techniques for ccRCC which 
may ultimately lead to intraoperative detection of ccRCC lesions was evaluated.
Chapter 2 provides an overview of the literature on previous efforts to develop 
successful strategies for both the detection and treatment of metastatic ccRCC using 
mAb G250/girentuximab.
Chapter 3 describes the use of 111In-girentuximab immunoSPECT in patients with 
lesions suspect for ccRCC. Patients with renal masses of unknown origin and patients 
with a history of ccRCC with lesions suspect for metastases on follow-up CT scanning 
were included in this report.
In chapter 4, a novel targeted fluorescence imaging technique was tested. These 
experiments helped studying the potential to detect ccRCC tumors with fluorescence 
imaging using mAb girentuximab conjugated with IRDye800CW.
To evaluate targeted fluorescence imaging in a model that better mimics the clinical 
situation, combined radionuclide and fluorescence imaging was tested by injecting 
dual-labeled antibody preparation 111In-G250-IRDye800CW in mice with small, 
intraperitoneally growing ccRCC lesions. Chapter 5 presents the results of this study.
17
Introduction
In chapter 6, the potential of radioimmunodetection and RIT with radiolabeled G250 
was evaluated in an advanced xenograft model with intraperitoneally growing ccRCC 
lesions. After optimizing the antibody dose, a RIT study was performed to determine 
the efficacy of a single injection of 177Lu-G250 in this model. 
An important challenge to successfully implement girentuximab-based RIT in patient 
care is optimizing the combination of this therapeutic approach with the current 
standard of care in metastatic ccRCC, namely treatment with tyrosine kinase inhibitors. 
Chapter 7 describes  a study investigating the effect of neo-adjuvant treatment with 
tyrosine kinase inhibitor sorafenib on the uptake of mAb girentuximab.
Chapter 8 presents the preliminary results of an ongoing phase II RIT trial. In this 
trial, patients with advanced metastatic ccRCC are treated with lutetium-177 labeled 
girentuximab at the maximum tolerated dose level. Both preliminary therapeutic 
efficacy as well as side effects are described.
18
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Summary
Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma 
(RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment 
of metastatic RCC, both in terms of improvement of progression-free survival and 
limitation of toxicity. For this reason, radionuclide imaging and radionuclide therapy 
are extensively investigated. This review provides an overview of the current progress 
in molecular imaging and radionuclide therapy in clear cell RCC (ccRCC) and will focus 
on promising detection and therapy strategies targeting the Carbonic Anhydrase IX 
antigen, which is expressed in ccRCC.
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Introduction
Renal cell carcinoma (RCC) accounts for approximately 2% of the total cancer incidence. 
The worldwide mortality of this disease exceeds 100,000 per year and has been stable 
for the last few years [1–3]. Surgical resection is usually the first choice in case of 
localized disease, but approximately 30% of patients with RCC present with metastatic 
disease and recurrence occurs in approximately 40% of patients treated for a localized 
tumor.[4,5] Unfortunately, conventional imaging studies cannot reliably distinguish 
benign solid lesions from RCC, which frequently poses a diagnostic problem for 
clinicians. Ultrasound or computed tomography (CT)-guided biopsies have a relatively 
high sensitivity and specificity [6,7], but are invasive and require careful observation 
of the patient after the procedure. Adequate characterization of suspect lesions based 
on imaging is essential to avoid invasive biopsies and superfluous surgery, both in 
localized and advanced disease.
Besides the clear diagnostic issues, there is an unmet need for improved treatment of 
this disease. Because of the large number of patients with advanced disease and the lack 
of a good response to chemotherapy [8,9], the search for therapeutic options has been 
progressively extended since the mid 1990s, resulting in various immunotherapeutic 
strategies, such as high-dose IL-2 and IFN-α, albeit with moderate success in few cases 
[9,10]. The development of agents targeting the VEGF pathway, such as bevacizumab 
(with IFN-α), tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, axitinib and 
sorafenib, and mTOR inhibitors, such as temsirolimus and everolimus, mark a new era in 
the treatment of metastatic RCC in terms of progression-free survival [11–19], but with 
several disadvantages. First, side effects, such as hypertension, fatigue, nausea, hand–
foot skin reactions and diarrhea, are frequently seen and little is known regarding the 
long-term effects of these agents [20]. Second, these agents have a cytostatic effect 
on advanced disease, rather than a cytoreductive effect. As a result, treatment with 
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TKIs and mTOR inhibitors is chronic and cessation of treatment may lead to flare-up of 
the disease [21]. The search for novel systemic treatment strategies with less toxicity 
and significant antitumor effects has led to therapeutic regimens using radiolabeled 
antibodies specifically targeting tumor-associated antigens expressed on tumor cells. 
This review summarizes the current knowledge on radionuclide imaging of RCC, as 
well as the experience gained in radioimmunotherapy (RIT) trials in these patients.
Current molecular imaging modalities in clear cell RCC
Fluorine-18 (18F)-fluorodeoxyglucose (FDG)-PET has been widely investigated and 
is now an established molecular imaging modality for various malignancies. In RCC, 
the diagnostic accuracy depends on the tumor grade and the FDG uptake being 
higher in dedifferentiated tumors, which is also observed in other tumor types. 
One of the major drawbacks of the detection of RCC with FDG-PET is the excretion 
of FDG via the kidneys, resulting in relatively high background activity. This can 
only be partly reduced by hyperhydration or administration of diuretics. Another 
disadvantage of imaging renal masses with FDG-PET is the reported false-positive 
signal in patients with angiomyolipoma, pericytoma and pheochromocytoma [22]. 
Wang et al. recently performed a meta-analysis of 14 articles on the role of FDG-
PET and FDG-PET/CT in both primary renal tumors and extrarenal lesions [23]. For 
primary renal tumors, the pooled sensitivity and specificity of FDG-PET was 62 and 
88%, respectively. For detecting metastases of RCC, the pooled patient-based 
sensitivity and specificity of FDG-PET was 79 and 90%, respectively. The use of FDG-
PET/CT improved the accuracy of detecting metastases as the pooled sensitivity 
and specificity increased to 91 and 88%, respectively. The authors conclude that 
combining FDG-PET and CT is mainly helpful in detecting extrarenal metastasis rather 
than renal lesions. However, the total number of studies assessing the role of FDG-
PET/CT evaluated in this meta-analysis is limited and further studies are warranted.
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Other PET tracers, such as 18F-thymidine [24], 18F-fluoromisonidazole [25] and carbon-
11-acetate [26], were also investigated in patients with RCC and, although reasonably 
good accuracy has been reported, the exact role of these tracers has not yet been 
studied in larger trials.
Carbonic Anhydrase IX and girentuximab
In 1986, Oosterwijk et al. described a monoclonal antibody (G250) that targeted an 
antigen highly expressed in clear cell RCC (ccRCC), the most common renal malignancy 
found in approximately 80–85% of cases [27]. A role as a carrier for the treatment 
of ccRCC was suggested. Later, a chimeric version of the monoclonal antibody 
G250 (cG250) was constructed and designated girentuximab [28]. The antigen was 
later recognized as a member of the Carbonic Anhydrase (CA) family and has been 
denominated MN/CA9/CAIX in the literature [29,30]. The CAs form a family of enzymes 
that catalyze the reversible reaction CO
2
 + H
2
O  HCO
3
− + H+, making these enzymes 
key players in the regulation of intra- and extra-cellular pH, and fluid balance. CAIX is 
ubiquitously expressed in ccRCC and not in normal renal tissue. Other types of RCCs, 
such as papillary RCCs, unclassified RCCs and Xp11.2 translocation RCCs, also have some 
membranous expression of CAIX however, ccRCCs more often and more consistently 
demonstrated high (up to 94%) expression compared with any other tumor type 
[31,32]. An extensive study by Leibovich et al. showed that CAIX is also expressed at 
low levels in the gastric mucosa, pancreatobiliary epithelium, small intestine crypt 
base, mesothelial cells, ovarian surface epithelium and fetal rete testis, but was not 
found in the normal kidney [33]. Many studies have focused on the potential of CAIX to 
predict clinical outcome, but no consensus has been reached [32–36], although high 
levels of CAIX seem to correlate with a better response to IL-2 therapy [37].
Because of the specific expression of CAIX on primary, as well as metastatic, ccRCC 
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tumors, the antigen is considered to be an excellent target for imaging of both localized 
and advanced disease. To date, several thousand girentuximab injections have been 
performed worldwide in several clinical trials since its introduction, and no severe side 
effects or allergic reactions to the antibody infusions performed in these studies were 
reported (for detailed toxicity data see [38,39]).
CAIX-mediated radioimmunodetection
Several clinical trials have demonstrated the possibility of detecting CAIX-expressing 
ccRCC lesions using girentuximab labeled with iodone-131 (131I), iodone-124 (124I) 
or indium-111 (111In). In a phase I protein dose-escalation study to determine 
the pharmacokinetics, toxicity, immunogenicity and imaging characteristics of 
131I-girentuximab, clear antibody targeting was observed in patients with CAIX-positive 
tumors at the optimum protein dose of 5–10 mg [40]. In a head-to-head comparison 
with FDG-PET, 131I-labeled girentuximab was found to be inferior at detecting ccRCC 
metastases [41]. These results led to the search for alternative radionuclides with 
more suitable characteristics to improve scintigraphic imaging. In an intrapatient 
comparative study, labeling girentuximab with the radiometal 111In proved to be 
superior to 131I in terms of imaging characteristics and increased tumor:blood ratios. 
With the 111In-labeled tracer, 47 lesions were detected, compared with 30 lesions with 
the 131I-labeled tracer [42]. In a larger clinical study, 111In-girentuximab proved to be a 
helpful diagnostic tool in both localized and metastatic ccRCC [43]. In addition to trials 
with different single-photon emission computed tomography (SPECT) tracers, the PET 
tracer 124I-girentuximab was extensively investigated to preoperatively visualize the 
presence of ccRCC. In a phase I trial in 26 patients scheduled for nephrectomy, 15 out of 
a total of 16 ccRCC lesions were detected, resulting in a sensitivity of 94%. Because of the 
high specificity (100%; 95% CI: 66–100), and negative (90%; 95% CI: 55–100) and positive 
(100%; 95% CI: 78–100) predictive values, it was concluded that 124I-girentuximab 
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immunoPET can identify ccRCC accurately, and help in clinical decision-making when 
dealing with renal masses of uncertain origin [44]. A subsequent study by Pryma et al. 
found a significant correlation between the PET measurements and autoradiography 
of the surgical specimens of the aforementioned clinical trials, suggesting immunoPET 
may be useful in quantitatively assessing antigen targeting by antibody-based 
therapies [45]. Recently, a large multicenter study comparing the diagnostic accuracy 
of 124I-girentuximab PET/CT with that of diagnostic CT for the detection of ccRCC in 
presurgical patients with renal masses was completed. Of the 226 patients enrolled, 
204 were infused with 185 MBq 124I-girentuximab 2–6 days prior to image acquisition 
and, eventually, 195 patients were evaluated. CT scanning was performed within 
48 hours of 124I-girentuximab PET/CT. This study confirmed the high accuracy of 
124I-girentuximab as the reported sensitivity (86%; 95% CI: 75–97) and specificity 
(86%; 95% CI: 69–100) were markedly higher than those of conventional CT [46,47].
In general, due to the better spatial resolution of PET compared with SPECT, smaller 
lesions can be visualized and a more exact localization of lesions can be expected with 
PET. However, the performance of 111In-girentuximab and that of 124I-girentuximab has 
not been directly compared to date. Animal data suggest better delineation of lesions 
is possible with zirconium-89 (89Zr)-labeled girentuximab immunoPET compared with 
111In-girentuximab immunoSPECT [48].
Whether girentuximab imaging is also helpful in evaluating treatment response of 
TKIs is currently subject to investigation [49]. In a recently completed clinical trial, a 
markedly decreased uptake of 111In-girentuximab after treatment with the TKI sorafenib 
was found [50,51]. There was no indication that sorafenib treatment affected CAIX 
expression. Therefore, this effect is most likely caused by the destruction of the tumor 
vasculature, resulting in reduced delivery and tumor penetration of the antibody. 
Although no data have been published regarding the effect of other TKIs in humans, 
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a similar effect can be expected with sunitinib and pazopanib as these agents have 
the same mode of action. Limited data from animal experiments suggest increased 
antibody uptake after discontinuation of sunitinib treatment, presumably due to rapid 
rebound neovascularization [21].
RIT in ccRCC
Extensive research on the development of RIT has yielded a few major breakthroughs, 
mainly in the treatment of malignant non-Hodgkin’s lymphoma with the approved 
90Y-ibritumomab tiuxetan (Zevalin®; Spectrum Pharmaceuticals, Inc., NV, USA) and 
131I-tositumomab (Bexxar®; GlaxoSmithKline, London, UK) [52-55]. RIT has also been 
studied in a number of solid tumors, albeit less successful in terms of clinical response. 
The observation that girentuximab could specifically target ccRCC lesions or guide 
radionuclides to malignant lesions has stimulated studies on the development of 
antibody-mediated therapy and RIT for ccRCC. Several clinical trials were conducted 
with the unlabeled ‘cold’ antibody girentuximab as an adjuvant therapy after 
nephrectomy. Although data are yet to be published, it has been reported that the 
large, recently completed phase III ARISER trial [56] did not meet its primary endpoint 
of median disease-free survival [57]. Currently, subanalyses of the degree of CAIX 
expression and clinical outcome are ongoing.
The first RIT trial was conducted to determine targeting and toxicity of 131I-labeled 
murine G250. A total of 33 patients with metastatic ccRCC were treated with escalating 
doses ranging from 555 to 3330 MBq/m2 of 131I-labeled G250. Three of the 15 patients 
treated at the maximum tolerated dose (MTD) of 3330 MBq/m2showed stable disease, 
which lasted up to 18 weeks post-treatment. The major drawback of the use of murine 
G250 was the formation of human antimouse antibodies in all patients after injection, 
restricting therapy to a single infusion [58]. The first clinical trial using girentuximab 
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labeled with 131I was a phase I dose-escalation study. In this trial, all patients (n = 
12) received a diagnostic infusion of 222 MBq 131I-girentuximab. If targeting of the 
antibody in metastases was observed, a therapeutic infusion with girentuximab 
labeled with a high dose of 131I followed. Besides a partial response in one patient, no 
objective responses were seen. Because grade IV hematological toxicity in the two 
patients who received a dose of 2775 MBq/m2 was observed, the MTD was set at 2220 
MBq/m2 [58]. In an attempt to limit the hematological toxicity of 131I-girentuximab RIT, 
a fractionated-dose study was initiated, in which patients received an initial dose of 
1110 MBq 131I-girentuximab. Whole-body activity was measured after 2–3 days and a 
second administration of 131I-girentuximab was administered to, again, reach a total 
of 1110 MBq of radioactivity in the body. This procedure was repeated until a whole-
body absorbed dose of 0.50 Gy was reached. Patients without disease progression 
were re-treated after recovery from hematological toxicity. In subsequent cohorts, 
the whole-body absorbed dose was increased by 0.25 Gy. A total of 15 patients were 
included in the trial. Despite disease stabilization in seven patients, no major clinical 
responses were seen. Formation of human antichimeric antibodies (HACA) was seen in 
two patients, prohibiting them from being treated continually. Although fractionated 
RIT with 131I-girentuximab was safe and feasible, hematological toxicity was not 
significantly affected by fractionation [60]. Another phase I/II trial evaluated the safety 
and efficacy of two sequential high-activity dose treatments with 131I-girentuximab. 
As in other trials, a scout dose preceded the therapeutic infusion of 131I-girentuximab. 
The therapeutic dose was at the predetermined MTD of 2220 MBq/m2. Patients with 
stable disease (or responders) were eligible to receive a second dose at 75% of the 
MTD of the first RIT cycle 12 weeks later. In the majority of patients, two cycles of 
131I-girentuximab could be safely administered without severe toxicity. In this study, no 
objective responses were observed, although two RIT doses resulted in stabilization of 
previously progressive disease in five out of 27 patients. The formation of HACA after 
multiple girentuximab administrations was observed in eight out of 27 patients [61]. 
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Dosimetric analysis of the imaging data obtained in this trial revealed that the radiation 
absorbed dose to the tumor was relatively low in larger lesions, whereas only lesions 
less than 5 g absorbed more than 50 Gy, suggesting that RIT is particularly suitable 
for the treatment of small-volume disease or treatment in an adjuvant setting [62].
Due to the limited clinical benefit obtained in the first clinical RIT trials, the search 
for more suitable radionuclides was initiated. A preclinical study revealed superior 
therapeutic efficacy of lutetium-177 (177Lu), yttrium-90 (90Y) or rhenium-186 (186Re)-
labeled girentuximab compared with 131I-labeled girentuximab. Tumor growth in mice 
was delayed most effectively by 177Lu-girentuximab, resulting in a median survival for 
the 177Lu group that was almost twice as long as that for the 131I group (294 vs 164 
days) [63]. This led to various additional animal experiments and ultimately in a phase 
I dose-escalation trial with 177Lu-girentuximab. Because the in vivo characteristics of 
111In-girentuximab are very similar to those of 177Lu-girentuximab, patients with 
advanced ccRCC initially received a scout dose of 111In-girentuximab to evaluate 
antibody uptake in tumor lesions. If at least one evaluable metastatic lesion <5 cm in 
diameter was visualized with 111In-girentuximab, 177Lu-girentuximab was administered 
at escalating doses from 1110 to 2590 MBq/m2 in cohorts of three patients per dose 
level. Approximately 70% of the patients showed stable disease after one treatment 
cycle and one patient had a partial response lasting up to 9 months. A total of 13 patients 
received two treatment cycles and four of them received three treatment cycles. In 
two patients, HACA formation was detected [64]. Currently, the subsequent phase II 
trial to determine the efficacy of multiple doses of 177Lu-girentuximab at the MTD of 
2405 MBq/m2 is ongoing [65]. If an objective response (at least stable disease) is seen 
after the first treatment cycle, patients are eligible for a maximum of two additional 
treatment cycles at 75% of the activity dose of the previous treatment cycle [65].
Another ongoing clinical trial is a phase I activity dose-escalation study using 
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90Y-girentuximab [66]. Similar to the 177Lu-girentuximab trial, patients first receive 
a scout dose of 111In-girentuximab and if there is evidence of targeting to lesions, 
90Y-girentuximab is administered. At least three patients per dose level will be followed 
for up to 8 weeks. The dose levels start at 7.4 MBq/kg 90Y and subsequent groups will 
be treated in 3.7 MBq/kg increments, with the last cohort increasing by 1.85 MBq/kg. 
In contrast to the previously mentioned phase I/II trial [64,65], patients will receive 
only one treatment. In both ongoing trials, a series of SPECT acquisitions is performed 
after administration of the scout dose, providing data for additional dosimetric studies. 
As postulated by several groups, individualized image-based dosimetry is probably 
required for the optimal therapeutic delivery of radiolabeled antibodies [67,68].
Conclusion
Conventional imaging with CT, MRI and FDG-PET is suboptimal in evaluating disease 
status in RCC due to its poor sensitivity. Radionuclide imaging has proven to be a useful 
tool in detection of localized and metastatic disease. Despite the recent emergence of 
angiogenesis inhibitors, there is still an unmet need to effectively treat metastatic RCC. 
Early reports of radioimmunotherapy targeting the CAIX antigen in ccRCC indicate 
great potential of this new treatment strategy, but further studies are needed to 
confirm these results.
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Future perspective
As a recent large, phase III clinical trial showed no therapeutic efficacy of 
unlabeled girentuximab in the adjuvant setting [56], future studies are more 
likely to focus on radioimmunodetection and RIT with radiolabeled girentuximab.
Radioimmunoscintigraphy with radiolabeled girentuximab holds great promise for 
the future, both in detecting localized and advanced disease. However, based on 
current data, it is not possible to conclude which radiotracer is superior in diagnostic 
performance. In the near future, a clinical trial with the PET tracer 89Zr-girentuximab 
will be initiated in our center, which will provide additional information regarding 
the use of girentuximab-based immunoPET in ccRCC. Besides the usefulness in 
radioimmunodetection, girentuximab is a potent carrier for RIT in ccRCC. However, 
there are still several hurdles to overcome before girentuximab-based RIT can be 
implemented as a standard treatment. As previously mentioned, it is not clear which 
patients benefit most from RIT. Past results indicate that RIT is mainly suitable for the 
treatment of small-volume disease or possibly as adjuvant treatment in selected cases, 
and more evidence regarding this topic is expected from the ongoing clinical trials with 
90Y and 177Lu-labeled girentuximab in the upcoming years [62]. Besides better patient 
selection in the future, advances in dosimetric analysis will presumably contribute to 
the improvement of RIT as the trade-off between efficacy and toxicity can be better 
tailored to the individual patient. Lastly, an important deficit in our current knowledge 
is how to optimally combine girentuximab-based RIT with the current standard of care 
in metastatic ccRCC. As described earlier, we recently found a markedly decreased 
uptake of 111In-girentuximab after treatment with the TKI sorafenib [50,51]. Data 
from this study suggest that the effect of girentuximab-based RIT would be severely 
hampered if given during TKI treatment. Further studies to evaluate the duration of 
this TKI-induced effect are needed and may prove to be a vital step to successfully 
combine TKI treatment and RIT for ccRCC patients.
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Abstract
 
Background
Improved and more frequent radiologic evaluation has resulted in increased 
identification of renal masses of unknown origin, which frequently pose a diagnostic 
dilemma for urologists.
Objective
Carbonic Anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal 
cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes 
CAIX an excellent target for imaging ccRCC lesions. We present our experience with 
immuno–single-photon emission computed tomography (immunoSPECT) imaging 
with the indium-111 (111In)–labeled anti-CAIX antibody girentuximab in patients 
presenting with either a primary renal tumor or a history of ccRCC and lesions suspect 
for metastases during follow-up.
Design, setting, and participants
Twenty-nine patients received 100–200 MBq 111In-labeled girentuximab. Whole-body 
and single photon emission computed tomography (SPECT) images were acquired 
after 4–7 days.
Intervention
Injection with 111In-girentuximab and image acquisition after 4–7 days.
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Outcome measurements and statistical analysis
Accuracy of 111In-girentuximab immunoSPECT.
Results and limitations
Distinct uptake of 111In-girentuximab was seen in 16 of 22 patients presenting with 
a renal mass. All renal masses proven to be ccRCC after resection (n = 15) were 
detected with 111In-girentuximab. Suspect lesions of six patients showed no uptake of 
111In-girentuximab. In these patients, ccRCC was not found, nor progression occurred. 
Seven patients with a history of ccRCC and possible metastatic lesions on follow-up 
computed tomography scans were imaged with 111In-girentuximab. In four of these 
patients, the lesions showed preferential uptake of 111In-girentuximab and local or 
systemic treatment was initiated. In three other cases, no 111In-girentuximab targeting 
was seen. During follow-up of these three patients, one showed progression, for which 
systemic treatment was started. In the two other patients, no progression occurred, 
suggesting a benign nature.
Conclusions
111In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients 
with a primary renal mass and to clarify the nature of lesions suspect for metastases in 
patients with a history of ccRCC.
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Introduction
Improved and more frequent radiologic evaluation has resulted in increased 
identification of small renal masses of unknown origin. Unfortunately, conventional 
imaging studies cannot reliably distinguish benign solid lesions from renal cell 
carcinoma (RCC). This frequently poses the dilemma for urologists of whether to 
perform a (partial) nephrectomy on a potentially benign mass or to refrain from 
surgery and enter patients with a potentially aggressive malignancy into a follow-up 
protocol until disease progression occurs. Specimens obtained by ultrasound- or 
computed tomography (CT)–guided biopsies have a relatively high sensitivity and 
specificity [1,2], but the procedures are invasive and require careful observation 
of the patient afterward. In addition, a recent report found a pooled sensitivity of 
fluorine-18 fluorodeoxyglucose positron-emission tomography (18F-FDG-PET) imaging 
for detecting primary RCC of only 62% [3]. Adequate characterization of these renal 
lesions based on imaging would be advantageous to avoid invasive biopsies and, more 
importantly, superfluous surgery. Similarly, unambiguous detection of lesions suspect 
for metastatic clear cell RCC (ccRCC) would be advantageous to start additional 
treatment.
Carbonic Anhydrase IX (CAIX) is a specific antigen for ccRCC [4,5]. CAIX catalyzes the 
reversible reaction CO
2
 + H
2
O ⇆ HCO
3
− + H+ and helps regulate the intra- and extracellular 
pH and fluid balance in the otherwise highly acid environment of the malignant cells. 
The antigen is not found in normal renal tissue nor in benign cysts, whereas high levels 
of expression are reported in up to 94% of the ccRCC cases [4,5]. Only very low levels 
are expressed in other organs, mainly in the upper gastrointestinal tract [5]. Because of 
its specific and high level of expression, CAIX is an excellent target for imaging ccRCC 
lesions. In 1986, the monoclonal antibody (mAb) girentuximab (G250) that recognized an 
antigen on RCC tumor cells was described [6]. The unknown antigen was later identified 
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as a member of the Carbonic Anhydrase family and has been denominated MN/CA9/
CAIX in literature [7,8]. To reduce the immunogenicity of the murine mAb, a chimeric 
version of G250 was constructed [9], which was denominated girentuximab. More than 
2500 girentuximab injections have been performed worldwide in several clinical trials 
since its introduction [10-17]. No severe side effects or allergic reactions to the antibody 
infusions have been reported to date. In 2007, Divgi et al. reported on the possibility of 
specifically detecting ccRCC preoperatively with positron-emission tomography (PET) 
using iodine-124 (124I)-labeled girentuximab in patients with renal masses [16]. In our 
center, girentuximab labeled with the gamma-emitting radionuclide indium-111 (111In) 
is used to detect ccRCC lesions. Single-photon emission CT (SPECT) with 111In-labeled 
girentuximab has several important advantages. Similar to 124I-girentuximab 
immunoPET, it is noninvasive and does not require the use of intravenous contrast 
agents, which makes it suitable for patients with an impaired renal function. In 
addition, it is easier to produce as an off-the-shelf agent than 124I-girentuximab, which 
requires specialized equipment and needs to be purified after the labeling procedure.
In this paper, we present our experience with 111In-girentuximab immunoSPECT in 
patients presenting with a primary renal tumor or having a history of ccRCC with 
lesions on follow-up imaging suspect for metastases.
Materials and methods
Radiolabeling of girentuximab
Girentuximab (cG250; Wilex AG, Munich, Germany) was conjugated with 
diethylenetriaminepentaacetic acid (DTPA) as described previously [18]. The 
girentuximab–DTPA solution was aliquoted into sterile vials (5 mg in 1.0 ml) and 
stored at −20 °C until use. After inclusion of a patient, the girentuximab-DTPA 
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conjugate was labeled with 100–200 MBq of 111In (Covidien, Petten, The 
Netherlands). The volume of 111In-DTPA–girentuximab was adjusted to 10 
ml with normal saline. Radiochemical purity of all preparations used in this 
study exceeded 95%, as determined by instant thin-layer chromatography.
Study design
In total, 111In-girentuximab immunoSPECT data from 29 patients were analyzed. 
Twenty-two patients with an incidentaloma were included, of whom 15 patients 
participated in a molecular imaging trial (NCT00602862) [19]. In addition, 
111In-girentuximab imaging data from seven patients with a history of localized ccRCC 
and who presented with lesions suspect for metastases were analyzed. Informed 
consent was obtained from all patients. 111In-girentuximab was infused as a slow 
bolus. After administration, patients were observed for 30 minutes. The dose was 100 
MBq 111In for patients in the molecular imaging trial, and 185–200 MBq 111In for all 
other patients. Whole-body and SPECT images were acquired 4–7 day after injection.
Imaging
Whole-body scans were acquired 4–7 days after injection using a dual head 
γ-camera (E.cam or Symbia T16; Siemens Inc, Munich, Germany) equipped with 
parallel-hole medium-energy collimators (symmetric 15% window over 172 and 
247 keV) and a scan speed of 4 cm/min [10]. Subsequently, three-dimensional 
(3D) SPECT of the area of interest was acquired. All images were reviewed by 
nuclear medicine physicians and discussed in multidisciplinary tumor boards.
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Abbreviations: ccRCC= clear cell renal cell carcinoma, MTSCC= mucinous tubular spindle cell carcinoma
Table 1. Patient and imaging characteristics
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Results
Patients
In total, 111In-girentuximab immunoSPECT data from 29 patients were analyzed. Patient 
characteristics and imaging data are summarized in Table 1. Twenty-two patients were 
scanned because of an incidentaloma of the kidney and seven patients were scanned 
to detect metastases of ccRCC. 111In-girentuximab infusions were well tolerated and no 
side effects were observed.
Imaging
Renal mass
Of the 22 patients who presented with a renal mass of unknown origin, clear 
preferential uptake of 111In-girentuximab was observed in the lesions of 16 patients. 
These lesions were resected and histopathologic examination revealed ccRCC in 15 
patients, all detected by 111In-girentuximab imaging. A typical example of a positive 
111In-girentuximab scan is shown in Figure 1. In one of 16 patients, 111In-girentuximab 
targeting was found in a type 2 papillary RCC with CAIX expression (Patient 9). The 
CAIX expression in this particular patient was found in a vital tumor region within a 
necrotic part of the surgical specimen, suggesting this particular expression could be 
hypoxia driven (Figure 2). This was the only case in which targeting was seen in a non–
clear cell subtype. Overall, in this group of patients, the positive predictive value (PPV) 
of 111In-girentuximab imaging for ccRCC was 94%.
 
In six patients presenting with a renal mass, no targeting of 111In-girentuximab was 
observed. Four of these patients underwent surgery as planned (Patients 11, 16, 
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19, and 21). Histopathologic evaluation revealed two cases of benign oncocytoma 
(Patients 16 and 19), a chromophobe in Patient 11, and a mucinous tubular and 
spindle cell carcinoma subtype in Patient 21. Patient 21 also presented at diagnosis 
with a lung lesion, which proved to be a benign chondrohamartoma. Both the 
renal tumor and the lung lesion were not targeted with 111In-girentuximab. The 
remaining two patients (Patients 3 and 15) were closely monitored with repeated CT 
scans. No growth of the renal mass occurred in the follow-up period (>24 months).
Figure 1. Posterior 111In-girentuximab image of 
Patient 14 with a small renal mass in the left kidney. 
An attempt to biopsy the lesion had failed and the 
patient underwent 111In-girentuximab immunoSPECT. 
Besides normal uptake in the right upper abdomen 
(liver and upper gastrointestinal tract), clear targeting 
of 111In-girentuximab is seen in lesion (arrow). 
Histopathologic examination revealed a clear cell renal 
cell carcinoma with a 12-mm diameter.
Figure 2. Carbonic Anhydrase IX (CAIX) 
expression in a type 2 papillary tumor. 
CAIX expression was found in a vital tumor 
region within a necrotic part of the surgical 
specimen, suggesting hypoxia- driven 
expression.
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Detection of clear cell renal cell carcinoma metastases
Seven patients with a history of ccRCC and possible metastatic lesions on follow-up 
CT scans were imaged with 111In-girentuximab (Table 1). In four patients, positive 
111In-girentuximab imaging was observed. Patient 23 had abdominal masses near the 
rectus abdominis muscle (36 mm) and between the spleen and diaphragm (16 mm). 
Targeting of 111In-girentuximab was seen in both lesions. Both lesions were resected, 
and both proved to be ccRCC metastases. Patient 25 presented with a large, cystic, 
abdominal lesion suspect for local recurrence. Focal targeting of 111In-girentuximab in 
the large cystic mass was seen. Histopathologic examination revealed a local recurrence 
of ccRCC. Patient 27 presented with an enlarged para-aortal lymph node of 15 mm 10 
years after the initial diagnosis of ccRCC. 18F-FDG-PET was negative. Moderate targeting 
of 111In-girentuximab was detected on the whole-body images, and the patient 
underwent a retroperitoneal lymph node dissection. Histology showed subtotal lymph 
node infiltration of CAIX-positive malignant cells. Patient 29 had a liver lesion of 0.5 
cm on follow-up CT scan (Figure 3) 6 months after nephrectomy because of ccRCC. 
The lesion was biopsied, but unfortunately, specimen histology was not conclusive. 
111In-girentuximab imaging was performed 4 weeks later and showed targeting of the 
antibody in this lesion, strongly suggesting metastatic disease. Follow-up CT scanning 
2 months thereafter confirmed disease progression, after which systemic treatment 
was started (Figure 3). Patient 24 had known metastatic ccRCC and transient interstitial 
pneumonitis due to interferon-α therapy. 111In-girentuximab immunoSPECT was 
performed to assess the nature of multiple, new, pulmonary abnormalities during 
sunitinib treatment because it was uncertain that these represented active tumor 
tissue. In contrast to the already known metastases, no targeting in the new lung 
lesions was seen. Therefore, it was hypothesized that the abnormalities were possibly 
a flare-up of the interstitial pneumonitis due to the sunitinib treatment, and treatment 
was discontinued in view of the otherwise stable disease. No progression of these lung 
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Figure 3. Images of Patient 29, who had a history of clear cell carcinoma. After tumor nephrectomy, the 
patient entered active surveillance. (A) On follow-up computed tomography (CT) scan, a 5-mm lesion in 
segment 8 of the liver was detected, and biopsy of this lesion was nonconclusive. (B) Clear targeting of the 
liver lesion on the subsequent 111In-girentuximab immunoSPECT was detected. (C) On a follow-up CT scan 2 
months after immunoSPECT, growth of the lesion was detected and systemic therapy was started. 
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lesions occurred for >18 months, suggesting a nonmalignant nature. Patient 26 had 
a history of localized ccRCC and presented with a slowly growing cystic lesion of 3.1 
cm located in the pancreas. Unfortunately, no histology could be obtained because 
of the localization of the lesion. Scintigraphy showed ambiguous targeting, possibly 
because of the cystic nature of the lesion. The lesion slowly progressed over time, for 
which sunitinib treatment was initiated. Patient 28 was referred to our center because 
of suspicion of local recurrence after radiofrequency ablation (RFA) of a primary ccRCC 
lesion. A biopsy specimen of the lesion was obtained; however, the histopathologic 
analysis was inconclusive. In addition, no targeting of 111In-girentuximab in the abdominal 
mass was detected. This patient was closely followed with repeated CT scans. No 
growth of the lesion occurred in a period of >12 months, suggesting the abnormalities 
seen on CT could be due to the reactive inflammatory response to the RFA treatment.
Discussion
In this retrospective analysis of our experience with 111In-girentuximab immunoSPECT 
in patients suspected of (recurrent) ccRCC, specific and high levels of radiolabeled 
antibody targeting was seen in all renal tumors of the ccRCC subtype, as demonstrated 
by confirmative histopathologic analyses, but not in benign lesions. PPV for detecting 
primary RCC lesions of the clear cell subtype was very high, as only one of 16 malignant 
tumors had a different histology. This indicates that if targeting of 111In-girentuximab is 
detected in a renal tumor, there is a clear need for surgical intervention. Our observations 
are in agreement with the clinical study with 124I-girentuximab immunoPET [16]. This 
study reported a detection rate of 15 of 16 cases of ccRCC (one negative study in a largely 
necrotic ccRCC) and absent targeting in 9 of 9 patients with non–ccRCC (including two 
papillary RCCs). Recently, a large, comparative, multicenter study of 124I-girentuximab 
PET/CT versus diagnostic CT for the detection of ccRCC in presurgical patients with renal 
masses was completed. This study confirmed the high accuracy of 124I-girentuximab, 
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as the reported sensitivity (86%; 95% confidence interval [CI], 75–97) and specificity 
(86%; 95% CI, 69–100) were markedly higher than those of conventional CT [20].
In addition to detection of primary ccRCC, we demonstrated that 111In-girentuximab 
imaging can be a helpful, noninvasive tool for clinical decision making in patients with 
a history of ccRCC who present with lesions suspect for metastases, particularly in cases 
with inconclusive conventional imaging or biopsy-specimen histology. Although the 
presence of ccRCC is unlikely in the patients in whom no histopathologic confirmation 
was obtained, false-negative findings in these particular patients cannot be ruled 
out completely because targeting of 111In-girentuximab is dependent on the degree 
and extent of CAIX expression. Although the vast majority of renal ccRCC lesions do 
express high levels of CAIX [6,7], inevitably a small subset of these lesions will not be 
detected due to the absence or low abundance of antigen expressed in the tumor cells. 
In addition, cystic lesions or subtotally ccRCC-infiltrated lymph nodes can be difficult to 
detect (eg, Patients 25, 26, and 27) due to the low numbers of CAIX-expressing cells. For 
solid tumors located in the kidney, a negative 111In-girentuximab immunoSPECT makes 
the presence of ccRCC highly unlikely, although another renal malignancy cannot be 
ruled out. Active surveillance or biopsy in patients with negative 111In-girentuximab 
immunoSPECT is warranted to further assess the nature of the suspect lesions.
It remains to be determined whether girentuximab-based radioimmunodetection is 
also helpful for response evaluation to systemic treatment like tyrosine kinase inhibitors 
(TKIs). In an imaging study using the 111In-labeled mAb bevacizumab, a markedly 
decreased uptake of the antibody in the renal tumors after treatment with the TKI 
sorafenib was seen. The decreased targeting was most likely due to the destruction 
of the tumor vasculature, which results in a reduced delivery and accumulation of the 
antibody in the tumor [21]. The effect of sorafenib on 111In-girentuximab uptake appears 
to be very similar [22]. Although no data have been published about the effect of other 
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TKIs on antibody targeting in humans, a similar effect can be expected with sunitinib 
and pazopanib, as these agents have the same mode of action. Currently, a clinical trial 
that focuses on the potential of 124I-girentuximab PET to detect early treatment response 
to sunitinib is ongoing (NCT01582204) [23] and is expected to give more insight to 
the role of radioimmunodetection in monitoring ccRCC during treatment. Distinct 
advantages of immunoPET as compared to immunoSPECT are the superior resolution, 
the shorter duration for full, 3D image acquisition, and the potential for quantitative 
analysis of tumor targeting. In contrast, the radiation burden after administration of 
typical radiation doses of 124I and zirconium-89 (89Zr) is markedly higher than that of 
111In. From the currently available data, we cannot deduce whether a clear difference in 
the diagnostic performance of immunoSPECT and immunoPET exists. A study with 89Zr-
girentuximab immunoPET will be initiated in 2013 and will hopefully clarify this matter.
Conclusions
111In-girentuximab immunoSPECT is a helpful, noninvasive tool to further characterize 
incidentalomas of the kidney. Where there is targeting of the tumor, surgical 
intervention is warranted. In addition, it can be used to clarify the nature of lesions 
suspect for metastases in patients with a history of ccRCC.
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Abstract
Near-infrared dye-tagged antibodies can be used for sensitive detection of tumor tissue 
in vivo. Surgery for clear cell renal cell carcinoma (ccRCC) might benefit from optical 
imaging by facilitating intra-operative detection of Carbonic Anhydrase IX (CAIX)-
expressing tumor lesions with chimeric monoclonal antibody (mAb) girentuximab, 
which has shown excellent imaging capabilities for ccRCC. Here we studied the 
potential of fluorescence imaging to detect ccRCC tumors with in nude mice with RCC 
xenografts by using mAb girentuximab conjugated with IRDye800CW, using SPECT 
imaging as a reference.
Methods
Groups of athymic BALB/c mice with subcutaneous CAIX-positive SK-RC-52 ccRCC 
tumors were injected intravenously with iodine-125 (125I)-labeled girentuximab-
IRDye800CW or 125I-labeled girentuximab. For determination of the specificity of the 
accumulation of the anti-CAIX antibody conjugate in ccRCC, separate groups of mice 
bearing a CAIX-positive (SK-RC-52) and CAIX-negative tumor (SK-RC-59) received 
125I-girentuximab-IRDye800CW or 125I-labeled MOPC21-IRDye800CW (control mAb). 
Optical images and micro-SPECT images were acquired until 3 days after injection. 
Mice were euthanized after the last imaging session, and the biodistribution of the 
radiolabeled antibodies preparations was determined.
Results
Optical imaging and micro-SPECT imaging at 1 day after the injection of 
125I-girentuximab-IRDye800CW showed clear delineation of the CAIX-expressing 
ccRCC xenografts, and image contrast improved with time. Fluorescence imaging 
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and biodistribution studies showed high and specific uptake of 125I-girentuximab-
IRDye800CW in CAIX-positive ccRCC xenografts (SK-RC-52: 31.5 ± 9.6 %ID/g at 72 hours 
p.i.). Tumor uptake was specific, as very low uptake of 125I-girentuximab-IRDye800CW 
was noted in the CAIX-negative SK-RC-59 tumor (4.1 ± 1.5 %ID/g) and no uptake of the 
control mAb 125I-MOPC21-IRDye800CW was noted in the CAIX-positive SK-RC-52 tumor 
(1.2 ± 0.1 %ID/g).
Conclusion
Subcutaneous CAIX-expressing ccRCC xenografts were visualized by optical imaging 
with 125I-girentuximab-IRDye800CW. Optical images showed good concordance with 
micro-SPECT images. The accumulation of 125I-girentuximab-IRDye800CW in ccRCC 
tumors was high and specific. Girentuximab-IRDye800CW potentially could be used 
for the intraoperative detection CAIX-expressing tumors and assessment of residual 
tumor in the resection margins or metastatic lesions in patients with ccRCC. 
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Introduction
Renal cell carcinoma (RCC) accounts for approximately 2% of all malignancies [1]. 
Surgical resection is usually the first choice for localized disease, but when disease 
has metastasized, the prognosis is bleak. Because of the increased use of conventional 
radiological modalities, such as computed tomography (CT) and ultrasound 
(US), RCCs are being found more frequently and at earlier stages of the disease 
[2]. The recommended treatment for a localized RCC depends on the tumor size. 
Nephron-sparing surgery is performed for smaller RCCs (especially those ≤ 4 cm 
in diameter) [3] because overall survival data of T1 to T3 tumors are comparable for 
partial and radical nephrectomy [4]. Negative surgical resection margins are crucial 
for the clinical outcome because they prevent additional surgical interventions [5]. 
Therefore, adequate characterization and resection of the renal tumor and metastatic 
lymph nodes is of utmost importance.
The use of near-infrared (NIR) imaging probes for improved tumor characterization and 
delineation during surgery is increasing, although clinical application has been limited. 
The sensitivity of NIR imaging might be extremely high, and because of the low tissue 
autofluorescence in this part of the light spectrum, the use of NIR imaging probes could 
yield optimal visualization of tissues of interest. Unfortunately, the limited penetration 
depth of the emitted light of these agents hampers whole body applications [6]. 
Fluorescent agent IRDye800CW, a typical example of a NIR dye, emits NIR 789 nm 
photons when excited at 774 nm. IRDye800CW can be stably coupled to targeting 
molecules, such as peptides and monoclonal antibodies (mAbs), and can be detected 
with a NIR imaging camera [7, 8].  For clear cell RCC (ccRCC) -the most common subtype 
of RCC, present in approximately 85% of the patients presenting with a malignant 
renal tumor- the chimeric mAb girentuximab (also known as cG250) could serve as a 
such a targeting molecule. Girentuximab specifically recognizes Carbonic Anhydrase 
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IX (CAIX), a tumor-associated antigen ubiquitously expressed in ccRCC. The use of 
girentuximab in radioimmunoscintigraphy and radioimmunotherapy to detect or treat 
ccRCC has been investigated extensively [9, 10]. Because of the high-level and specific 
targeting and accumulation of girentuximab in ccRCC tumors, we hypothesized 
that this antibody could also act as a carrier for the delivery of IRDye800CW in 
these tumors. The intravenous administration of girentuximab-IRDye800CW before 
(partial) nephrectomy might facilitate the sensitive, in vivo, intraoperative detection 
of positive resection margins, metastatic lymph nodes, or distant ccRCC metastases.
Here we characterized girentuximab-IRDye800CW in a subcutaneous mouse model. 
The antibody-IRDye800CW conjugate was radiolabeled to quantitatively determine 
the biodistribution. Studies were conducted to demonstrate tumor-specific and 
antigen-mediated uptake of the girentuximab-IRDye800CW conjugate. In addition, 
tumor targeting and biodistribution of the conjugate was compared with those of 
unconjugated radiolabeled girentuximab. This NIR imaging system could potentially be 
used intraoperatively to enhance tumor visualization and resection in the near future.
Materials and methods
ccRCC tumors in nude mice 
Cell lines
The ccRCC cell lines SK-RC-52 (CAIX-positive) and SK-RC-59 (CAIX-negative) 
were derived from metastases of primary ccRCC patients as described by 
Ebert et al [11]. Cells were cultured and washed as described previously [12]. 
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Animal model
The animal experiments were approved by the Internal Review Board of the Radboud 
University Medical Center, Nijmegen, The Netherlands, and were performed in 
accordance with that organization’s guidelines. Animals were housed and fed according 
to the Dutch animal welfare regulations. For obtaining subcutaneous tumors, 2x106-
3x106 cells were injected subcutaneously into the flanks of 6- to 8-week-old male 
BALB/c nu/nu mice (Janvier) and tumors grew to a size of 50-200 mm3 within 2-3 weeks. 
 
Imaging agents and labeling
mAb girentuximab
The isolation and immunohistochemical reactivity of mAb G250 have been described 
elsewhere [13]. For reducing the immunogenicity of murine G250 in humans, a chimeric 
version (girentuximab) has been developed [14]. mAb girentuximab is reactive with 
the transmembraneous glycoprotein CAIX (K
a
 = 4 x 109 M-1). Expression of CAIX on the 
cell surface of ccRCC cells is ubiquitous (>95%), whereas expression on normal tissues 
is restricted to the epithelial structures of the upper gastrointestinal tract and larger 
bile ducts [15, 16]. 
mAb MOPC21
MOPC21, a murine IgG1 mAb (Sigma-Aldrich) that is not directed against any known 
antigen, was used as a nonspecific control mAb in these studies. 
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Conjugation, radiolabeling and quality control 
Conjugation of mAb girentuximab and MOPC21 with IRDye800CW (LICOR 
biosciences) was performed according to the supplier’s protocol. One milligram 
of mAb was incubated with 0.03 mg IRDye800CW for 2 hours at room temperature 
in 1 mL of 10 mM phosphate buffer (pH 8.5). The reaction mixture was transferred 
into a Slide-A-Lyzer cassette (molecular weight cut-off: 10,000 Da) (Pierce) and 
dialyzed extensively against phosphate-buffered saline for 3 days to remove the 
unconjugated IRDye800CW. On average 1.6 IRDye800CW molecules were conjugated 
per mAb molecule, as determined spectrophotometrically. The concentration of the 
conjugate was adjusted to 1 mg/mL, and aliquots were stored in the dark at -20 ˚C 
until use. Girentuximab and girentuximab-IRDye800CW were radioiodinated with 
iodine-125 (125I) (PerkinElmer) by the IODO-GEN (Pierce) method [14]. 125I-girentuximab 
was purified by gel filtration on a PD10 column (Amersham Biosciences); elution 
was done with phosphate-buffered saline containing 0.5% bovine serum albumin. 
The specific activities of 125I-girentuximab and 125I-girentuximab-IRDye800CW was 
4.0 and 7.8 MBq/μg, respectively. In all experiments, a mAb dose of 5 μg was used.
The radiochemical purity of the radiolabeled mAb preparations was determined by 
instant thin-layer chromatography with silica gel strips (Biodex Medical Systems) 
and 0.1 M citrate buffer (pH 5.0) as the mobile phase. The labeling efficiency 
exceeded 90% for all antibody preparations. After purification by gel filtration on 
a PD10 column, the radiochemical purity of all preparations used in the studies 
exceeded 95%. The immunoreactive fractions of all radiolabeled girentuximab 
preparations, as determined on freshly trypsinized SK-RC-52 ccRCC cells essentially 
as described by Lindmo et al. [17], were greater than or equal to 79% for 
125I-girentuximab and greater than or equal to 67% for 125I-girentuximab-IRDye800CW. 
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Optical imaging and microSPECT imaging
Images were recorded at 1 hour, 1 day, and 3 days after intravenous mAb injection. 
Optical images were acquired with an IVIS Lumina imaging system (recording time, 
1-3 min; binning factor, 4; emission filter, ICG; field of view, 12.5; excitation filter, 745 
nm) (Caliper life sciences). Mice were placed in the prone position in the scanner 
and body temperature was maintained at 37 °C with a heated imaging stage. All 
animals were gas-anesthetized with a mixture of oxygen, N
2
O, and isoflurane. Micro-
SPECT images were acquired with a U-SPECT II micro-SPECT scanner (MILabs) by 
the use of the GP-RM 1.0 mm collimator tube with 75 pinholes [18]. SPECT images 
were reconstructed with ordered-subset maximization expectation (6 iterations; 
16 subsets; voxel size 0.1875 mm) using the U-SPECT-Rec software (MILabs). 
Study design
Changes in girentuximab biodistribution as a result of the conjugation of the mAb 
to IRDye800CW were assessed with 2 groups of 5 mice. Mice with a subcutaneous 
SK-RC-52 tumor were injected with either 125I-labeled girentuximab-IRDye800CW 
or unconjugated 125I-labeled girentuximab. Both groups were studied with micro-
SPECT imaging, and the group receiving 125I-girentuximab-IRDye800CW was also 
studied with optical imaging. Biodistribution studies were performed for both groups. 
For determination of whether tumor targeting of the girentuximab constructs was 
CAIX antigen-mediated, 2 groups of 6 mice with  subcutaneous CAIX-positive tumor 
(SK-RC-52) in the left flank and a subcutaneous CAIX-negative tumor (SK-RC-59) in the 
right flank were used. One group of mice received 125I-girentuximab-IRDye800CW, and 
the other group received nonspecific 125I-labeled MOPC21-IRDye800CW. Both groups 
Chapter 4
66
were studied with optical imaging as well as micro-SPECT imaging, and biodistribution 
studies were performed.
The specificity of girentuximab targeting to CAIX-expressing ccRCC tumors was studied 
with an additional group of 5 SK-RC-52–bearing mice. These mice were coinjected with 
125I-girentuximab-IRDye800CW and an excess (500 mg) of unlabeled girentuximab. 
Again, optical imaging as well as micro-SPECT imaging and biodistribution studies 
were performed.
For assessment of the feasibility of image-guided surgery for ccRCC tumors, 5 mice 
with subcutaneous CAIX-expressing tumors were injected intravenously with 
125I-girentuximab-IRDye800CW. Tumors were visualized with fluorescence imaging 
at 3 days after injection. Afterwards, the tumors were resected, and imaging of the 
mice was performed again to evaluate whether radical tumor resection was achieved.
 
Biodistribution studies
After the last images were acquired (3 days after injection), mice were euthanized, 
and the biodistribution of the radiolabel was determined. Tumors and samples of 
normal tissues (blood, muscle, lung, spleen, kidney, liver, small intestine, and stomach) 
were dissected and weighed, and counts were obtained with a γ counter (1480 
Wizard 399; PerkinElmer). The biodistribution results are reported as the percentage 
injected dose (%ID) per gram of tissue (%ID/g). The thyroid was also dissected, and 
counts were obtained; the results for this organ are expressed as the %ID. Counts for 
injection standards were obtained simultaneously to correct for radioactive decay.
Near infrared imaging in ccRCC
67
Statistical analysis
Statistical analysis was performed using t tests. Differences were considered 
significant at p value of less than 0.05 (2-sided). All values are expressed as mean ± SD.
Results
Optical images of mice bearing a subcutaneous CAIX-positive SK-RC-52 tumor and 
injected with 125I-girentuximab-IRDye800CW showed targeting of the tumor by the 
IRDye800CW-conjugated antibody preparation at 1 and 3 days after injection (Figure 
1B). No tumor uptake was detected at 1 hour after injection (data not shown). Micro-
SPECT images of the same animals confirmed the accumulation of 125I-girentuximab-
IRDye800CW in the CAIX-expressing tumor (Figure 1A). The biodistribution of the 
radiolabel in these mice is summarized in Figure 1D. The data (SK-RC-52 uptake, 6.9 
± 1.1 %ID/g; mean tumor weight, 0.09 ± 0.03 g) confirmed the preferential uptake of 
125I-girentuximab-IRDye800CW in the tumor, as visualized on the optical images and 
the micro-SPECT images.
Micro-SPECT images of SK-RC-52 tumor–bearing mice injected with 125I-girentuximab 
showed tumor uptake at 1 and 3 days after injection (Figure 1C). No tumor uptake 
was detected at 1 hour after injection (data not shown). The biodistribution data for 
125I-girentuximab confirmed the preferential tumor accumulation observed on the 
micro-SPECT images (14.8 ± 3.3 %ID/g; mean tumor weight, 0.09 ± 0.06 g) (Figure 1D).
At 3 days after injection, the levels of 125I-girentuximab-IRDye800CW in blood 
were significantly lower than those of 125I-girentuximab (2.7 ± 0.35 vs 7.1 ± 1.3 
%ID/g, respectively; p = 0.001), suggesting faster clearance of the IRDye800CW 
conjugated antibody preparation from the blood. However, tumor-to-blood ratios 
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Figure 1. (A) Micro-SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 1 and 3 days 
after injection of 125I-girentuximab-IRDye800CW. In addition to tumor uptake, minimal uptake in heart and 
thyroid was observed. (B) Optical images of same mouse at 1 and 3 days after injection (same image settings 
were used for days 1 and 3). Some reflectance-induced image artifacts on backs of mice were observed. 
(C) Micro-SPECT images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 1 and 3 days after 
injection of 125I-girentuximab. (D) Biodistribution of 125I-girentuximab-IRDye800CW and 125I-girentuximab 
in mice with subcutaneous SK-RC-52 tumor at 3 days after injection. Values are expressed as mean ± SD. 
T/B ratio = tumor-to-blood ratio.
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did not differ significantly between the IRDye800CW-conjugated antibody and 
the unconjugated antibody (2.6 ± 0.34 vs 2.1 ± 0.34 %ID/g, respectively; p = 0.053).
In the second experiment, we investigated the specificity of the CAIX-mediated 
targeting of girentuximab by administering 125I-girentuximab-IRDye800CW 
or 125I-MOPC21-IRDye800CW to mice with both a CAIX-positive tumor and a 
CAIX-negative tumor. Optical images and biodistribution data are shown in Figure 
2. At 3 days after injection, the uptake of 125I-girentuximab-IRDye800CW in the CAIX-
positive tumor was high (31.5 ± 9.6 %ID/g; tumor-to-blood ratio, 3.2 ± 2.0; mean tumor 
weight, 0.02 ± 0.01 g), whereas low uptake was observed in the CAIX-negative tumor 
(4.1 ± 1.5 %ID/g; tumor-to-blood ratio, 0.4 ± 0.2; mean tumor weight, 0.07 ± 0.11 g). 
Both tumor uptake and tumor-to-blood ratios were significantly different between 
CAIX-positive and CAIX-negative tumors (p = 0.003 and p = 0.018, respectively). 
No tumor uptake was detected at 1 hour after injection (data not shown). 
Figure 2. (A) Optical images of mouse bearing CAIX-positive SK-RC-52 tumor on left flank and CAIX-negative 
SK-RC-59 tumor on right flank (arrows) at 1 and 3 days after injection of 125I-girentuximab-IRDye800CW 
(same image settings were used for days 1 and 3). Some reflectance-induced image artifacts on backs 
of mice were observed. (B) Biodistribution at 3 days after injection of 125I-girentuximab-IRDye800CW or 
125I-MOPC21-IRDye800CW in mice with subcutaneous SK-RC-52 tumor and subcutaneous SK-RC-59 tumor. 
Values are expressed as mean ± SD.
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Mice injected with the nonspecific control conjugate 125I-MOPC21-IRDye800CW 
showed significantly lower tumor uptake (for CAIX-positive SK-RC-52, 1.2 ± 0.1 %ID/g; 
tumor-to-blood ratio, 0.4 ± 0.1; mean tumor weight, 0.03 ± 0.01 g; for CAIX-negative SK-
RC-59, 2.0 ± 0.5%ID/g; tumor-to-blood ratio, 0.560.4;meantumorweight, 0.01 ± 0.006 
g) than mice injected with 125I-girentuximab-IRDye800CW (p = 0.002 and p = 0.027, 
respectively).
In the third experiment, the nonspecific uptake of girentuximab-IRDye800CW in 
the tumors was assessed by injecting a group of 3 mice bearing SK-RC-52 tumors 
with 125I-girentuximab-IRDye800CW and an excess of unlabeled girentuximab. 
Micro-SPECT images acquired at 1 hour, 1 day, and 3 days after injection did not 
show any uptake of the radiolabeled mAb in the CAIX-expressing tumors (data 
not shown). Biodistribution studies confirmed that the nonspecific uptake of the 
IRDye800CW-conjugated antibody in these tumors was very low (0.91 ± 0.25 %ID/g; 
tumor-to-blood ratio, 0.31 ± 0.06; mean tumor weight, 0.13 ± 0.08 g) (Figure 3).
In the fourth experiment, 5 mice with subcutaneous CAIX-expressing tumors 
received 125I-girentuximab-IRDye800CW intravenously, and tumors were visualized 
with fluorescence imaging at 3 days after injection. Subsequently, the tumors 
Figure 3. Ex vivo biodistribution of 
125I-girentuximab-IRDye800CW and excess 
unlabeled girentuximab. T/B ratio = 
tumor-to-blood ratio. 
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were resected, and imaging of the mice was performed again to evaluate whether 
radical tumor resection was achieved. After resection, no residual tumor was 
detected by fluorescence imaging or by macroscopic examination (Figure 4).
Taken together, these results show that 125I-girentuximab-IRDye800CW can target 
CAIX-expressing tumors with high specificity and that this targeting can be assessed 
by micro-SPECT and NIR fluorescence imaging. Furthermore, these results demonstrate 
the feasibility of targeted fluorescence image-guided surgery for ccRCC tumors.
Discussion
In the present study, girentuximab-IRDye800CW was characterized in a 
subcutaneous ccRCC xenograft model. Ex vivo biodistribution studies 
demonstrated high-level and specific targeting and high tumor-to-blood ratios 
for girentuximab-IRDye800CW in CAIX-expressing tumors. Compared with 
Figure 4. (Left) Preoperative fluorescence image of mouse with subcutaneous growing ccRCC tumor lesion 
at 3 days after injection with 125I-girentuximab-IRDye800CW. (Middle) Tumor lesion was subsequently 
removed by fluorescence image–guided surgery. (Right) After resection, no residual tumor was detected by 
fluorescence imaging or macroscopically.
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girentuximab, the IRDye800CW-conjugated antibody preparation showed lower 
tumor uptake at 3 days after injection (Figure 1D), most likely because of faster 
clearance of the IRDye800CW-conjugated antibody from the circulation [8]. 
The preferential accumulation of dually labeled girentuximab in CAIX-expressing 
tumors was confirmed with both optical imaging and micro-SPECT imaging. Both 
imaging modalities showed that the radiolabeled girentuximab-IRDye800CW 
conjugate accumulated specifically in CAIX-positive tumors, whereas nonspecific 
mAb MOPC21-IRDye800CW conjugate did not. Moreover, girentuximab-IRDye800CW 
accumulated in CAIX-positive tumors but not in CAIX-negative tumors. These results 
clearly demonstrated that the accumulation of the girentuximab-IRDye800CW 
conjugate was antigen-mediated. The tracer uptake appeared to be higher in Figure 
1B than in Figure 2A because of attenuation of the fluorescence signal in tissues.
The feasibility of using girentuximab-IRDye800CW in optical imaging and 
image-guided surgery for CAIX-expressing tumors suggests a potential role for this 
tracer in the intraoperative detection of positive surgical margins or tumor-infiltrated 
lymph nodes in patients with ccRCC tumors.
The results of the present study are in line with the results of other preclinical and clinical 
studies of dual-label imaging. Terwisscha van Scheltinga et al. [19] reported specific 
and sensitive detection of tumor lesions in vivo when they used fluorescence-labeled 
antibodies targeting vascular endothelial growth factor or human epidermal growth 
factor 2 in a breast cancer xenograft mouse model. The animals in that study received 
a second injection with the same antibodies labeled with a positron-emitting 
radionuclide, zirconium-89, to enable a comparison between fluorescence imaging 
and PET imaging. The addition of a radioactive tracer seems to be indispensible for 
intraoperative tumor detection because of the limited depth of tissue penetration 
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of the optical signal. However, whether the coinjection of both an optical tracer and 
a radiotracer will produce the same results as the administration of a dually labeled 
tracer has not yet been determined. With coinjection, the biodistribution of the optical 
tracer could differ from that of the radiolabeled tracer; in contrast, with a dually labeled 
tracer, both signals originate from the same molecule. Nontargeted dually labeled 
tracers were applied for sentinel lymph node biopsy and resection after intratumoral 
injection of nanocolloid in a clinical setting [20]. The results clearly demonstrate 
improved lymph node detection, especially when positive nodes are located in 
lymph node-rich regions, for example in the case of prostate cancer or head and neck 
cancer [21, 22]. A study with patients who had ovarian cancer had already shown the 
feasibility and potential of this approach for intraoperative fluorescence imaging in 
a clinical setting [23]. Currently, a clinical trial is of the use of fluorescentce-labeled 
bevacizumab to enable image-guided surgery in patients with breast cancer is under 
way (NCT01508572). These preclinical and clinical studies demonstrate the feasibility 
of dual-modality imaging for image-guided surgery.
Although the present study demonstrated that the optical imaging of CAIX-expressing 
tumors is feasible, there are some limitations for the direct clinical translation of 
targeted fluorescence imaging in patients with ccRCC. 
In the present study, we used 125I for small-animal imaging and ex vivo biodistribution 
studies. Because of its long half life (59.4 days) and less favorable γ characteristics 
(γ energy = 35 keV), 125I is not suitable for SPECT imaging in the clinical setting. 
Labeling girentuximab-IRDye800CW with 124I or with the residualizing radiometal 
indium-111 by use of the chelator DTPA could enable preoperative molecular 
imaging in patients with ccRCC tumors and thus enabling both pre- and perioperative 
imaging in ccRCC tumors [24-27].  Recently, Divgi et al. [26] assessed the accuracy 
of 124I-girentuximab PET/CT in a large cohort of patients with a primary renal 
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mass scheduled for surgery. The authors found high sensitivity and specificity of 
124I-girentuximab PET/CT for detecting ccRCC lesions (86.2% and 85.9%, respectively); 
these results were concordant with prior experience with this tracer and suggest that 
this imaging modality could improve patient care in the preoperative setting [24]. 
A limitation of girentuximab-based imaging is that targeting depends on CAIX 
expression in tumor lesions. However, approximately 80% of malignant renal lesions 
are of the clear cell subtype, express CAIX, and therefore potentially can be imaged 
with girentuximab-IRDye800CW. 
The results of the present study endorse the tumor-specific targeting of girentuximab 
and indicate that a new application for girentuximab-based imaging—namely, the 
intraoperative detection of ccRCC tumors, positive resection margins, and metastases 
with fluorescence imaging—may be feasible. This approach may lead to better cancer 
management. Further studies in which orthotopic or metastatic models are used to 
evaluate the sensitivity and potential added value of this approach are warranted. 
Conclusion
CAIX-expressing subcutaneous ccRCC xenografts were visualized by optical imaging 
with 125I-girentuximab-IRDye800CW, with good concordance between fluorescence 
images and micro-SPECT images. The accumulation of 125I-girentuximab-IRDye800CW 
in ccRCC tumors was high and specific. The use of girentuximab-IRDye800CW for 
the intraoperative detection of CAIX-expressing tumor lesions and the assessment 
of residual tumor in resection margins or metastatic lesions in patients with ccRCC 
tumors may be feasible. Clinical studies are warranted to assess the safety, feasibility, 
and validity of this fluorescence imaging approach for patients with ccRCC tumors.
Near infrared imaging in ccRCC
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Abstract
 
Purpose
Tumor targeted optical imaging using antibodies labeled with near-infrared fluorophores 
is a sensitive imaging modality that might be used during surgery to assure complete 
removal of malignant tissue. In this study, the feasibility of dual modality imaging 
and image-guided surgery with a dual-labeled anti-Carbonic Anhydrase IX (CAIX) 
antibody preparation indium-111 (111In)-DTPA-G250-IRDye800CW was evaluated in 
mice with intraperitoneally (i.p.) growing clear cell renal cell carcinoma (ccRCC) lesions.
Methods 
BALB/c nu/nu mice with i.p. growing SK-RC-52 tumor lesions received 10 μg 
DTPA-G250-IRDye800CW labeled with 15 MBq of 111In (n=20) or 10 μg dual-labeled 
irrelevant control antibody NUH-82 (n=20). To evaluate when tumors could be 
detected, 4 mice per group were imaged weekly during five weeks with both SPECT/CT 
and the IVIS Lumina fluorescence imager, followed by ex vivo biodistribution studies.
Results
As early as one week after tumor cell inoculation, SPECT and fluorescence images 
showed clear delineation of the i.p. growing ccRCC lesions, with very good 
concordance between the SPECT/CT and fluorescence images. The high and specific 
accumulation of the dual-labeled antibody conjugate in the tumors was confirmed 
in the biodistribution studies. Maximum tumor uptake was observed one week after 
inoculation (G250: 58.5±18.7 vs NUH-82: 5.6 ± 2.3 %ID/g), but also on other time points 
high tumor uptake was observed.
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Conclusions
This study demonstrates the feasibility of dual modality imaging 
with dual-labeled antibody 111In-DTPA-G250-IRDye800CW in a ccRCC model. Both 
SPECT and fluorescence images clearly showed specific accumulation of the tracer 
in the tumors, with excellent concordance between the imaging modalities. These 
results indicate that pre- and intraoperative detection of CAIX-expressing tumors, 
positive resection margins, and metastases might be feasible with this approach.
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Introduction
To accomplish radical excision of tumor tissue in oncological surgery, intraoperative 
imaging may be applied. For example, for sentinel node procedures with the use 
of a gamma detector is a well-established technique in patients with melanoma, 
breast cancer, and other malignancies [1-3]. Recently, studies have shown that the 
success rate of these procedures increases with the addition of a near infrared (NIR) 
fluorescent label [4-6]. Although sentinel node procedures are helpful in guiding 
the surgeon to the first draining lymph node, they do not provide information 
about the nature of the lymph nodes. Tumor targeting molecules labeled with 
fluorescent dyes, however, can aid in both the intraoperative detection and accurate 
delineation of malignant lesions, and thus enabling image-guided surgery of 
primary tumors, metastases and the detection of positive resection margins [7]. 
A major drawback of all fluorescence imaging techniques is the limited penetration 
depth of emitted light in biological tissue. By combining radionuclide and fluorescent 
tracers, a powerful complementary imaging system that overcomes the limitations of 
each individual modality can be developed for improved in vivo detection of tumors 
[8-10].
The fluorophore IRDye800CW is a NIR dye that is manufactured under cGMP and 
approved for use in clinical trials. This fluorescent dye emits near infrared 789 nm 
photons when excited at 774 nm and can be coupled to tumor specific targeting 
molecules such as monoclonal antibodies (mAbs), and detected intraoperatively with 
a NIR imaging camera. 
For clear cell RCC (ccRCC), which accounts for approximately 85% of the malignant 
renal tumors, G250 (chimeric mAb also known as girentuximab) is the most 
promising targeting mAb known. The use of G250 in radioimmunodetection and 
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radioimmunotherapy to detect or treat ccRCC has been investigated extensively, both 
in the preclinical and clinical setting [11, 12]. G250 specifically recognizes Carbonic 
Anhydrase IX (CAIX), a tumor-associated antigen ubiquitously expressed in primary 
ccRCC and its metastases. Because of the high and specific targeting of G250 in all 
CAIX-positive lesions (both primary tumors and metastases), this antibody could act as 
a potent carrier for the delivery of both the radiotracer and the NIR dye in these lesions. 
As we recently described, such a dual modality imaging system enables preoperative 
Single Photon Emission Computed Tomography (SPECT) and intraoperative tumor 
detection by means of the radioactive and NIR signal [13]. In this study, we describe 
indium-111 (111In)-DTPA-G250-IRDye800CW and show the feasibility of dual modality 
imaging and image-guided surgery in an intraperitoneal (i.p.) ccRCC model.
Materials and methods
ccRCC tumors in nude mice
Animals
All experiments were conducted in accordance with the principles laid out by 
the revised Dutch Act on Animal Experimentation (1997) and approved by the 
institutional Animal Welfare Committee of the Radboud University Nijmegen. 
Animals were housed and fed according to the Dutch animal welfare regulations. 
The experiments were performed in female nude BALB/c nu/nu mice (8-10 
weeks old) weighing 20–25 g (Janvier, le Genest-Saint-Isle, France). Mice were 
accustomed to laboratory conditions for at least one week before experimental 
use and housed under nonsterile standard conditions in filter-topped cages with 
free access to chlorophyll-free animal nutrition (Ssniff, Soest, Germany) and water. 
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Cell lines and induction of tumors
Intraperitoneal tumor growth was induced by i.p. injection of 0.2 mL of a suspension of 
3x106 SK-RC-52 cells, resulting in tumor nodules in the peritoneal cavity ranging from 
submillimeter to 5 mm in diameter after 1-5 weeks, which was in concordance with 
our previous experience with this model [14]. SK-RC-52 is a CAIX–expressing human 
ccRCC cell line which was acquired from the Memorial Sloan-Kettering Cancer Center 
(New York, USA). The cell line was previously described by Ebert et al. [15] and tested 
for authenticity by short tandem repeat profiling in August 2013 (DSMZ, Braunschweig, 
Germany). 
Study design
Athymic female BALB/c nu/nu mice injected i.p. with 3 x 106 SK-RC-52 cells as 
previously described [14]. After tumor cell inoculation, animals were divided in two 
groups of twenty mice. Based on our previous results in this i.p. xenograft model, an 
antibody protein dose of 10 μg was used [14]. One group was i.v. injected with 10 μg 
DTPA-G250-IRDye800CW labeled with 15 MBq 111In prior to imaging, the other group 
received 10 μg dual-labeled irrelevant isotype-matched control antibody NUH-82 [16]. 
To evaluate when tumors could be detected, 4 mice per group were imaged with both the 
microSPECT/CT and the IVIS Lumina optical imager 48 hours post injection (p.i.) weekly. 
84
Chapter 5
Imaging agents and labeling
Antibodies
G250 is a murine IgG1 mAb which is directed against the CAIX antigen expressed in 
ccRCC. NUH-82 is a murine IgG1 mAb not directed against any known antigen in the 
nude mice and was used as a negative control.
 
Conjugation, radiolabeling and fluorescent labeling
G250 and NUH-82 were conjugated with IRDye800CW-NHS (LICOR biosciences, Lincoln, 
NE, USA) according to the supplier’s protocol. Briefly, one mg mAb was incubated with a 
6-fold excess IRDye800CW and stirred for 3 hours at room temperature. After solving the 
mixture in a 0.1 M sodium carbonate buffer (pH 8.5), it was purified using a PD-10 column.
After the conjugation with IRDye800CW, mAb G250 and NUH-82 were conjugated 
with diethylenetriaminepentaacetic acid (DTPA) as described previously [17]. The 
reaction mixture was transferred into a Slide-A-Lyzer cassette (molecular weight 
cut-off: 20,000 Da, Pierce, Rockford, IL, USA) and extensively dialysed against 0.25 M 
ammonium acetate  (pH 5.4) for three days to remove the unconjugated IRDye800CW 
and DTPA. On average 1.1 IRDye800CW molecules were conjugated per mAb molecule 
as determined spectrophotometrically. The dual-labeled antibody preparations were 
stored in the dark at 4 ˚C until use.
111InCl
3
 was obtained from Covidien (Petten, The Netherlands). Ten μg G250  dissolved 
in 0.25 M ammonium acetate buffer (pH 5.4) and radiolabeled with 15 MBq 111InCl
3
 
in two volumes of 0.1 M MES (Sigma-Aldrich, Zwijndrecht, The Netherlands). After 
20 minutes of incubation at room temperature, 50 mM EDTA was added to a final 
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concentration of 5 mM (Sigma-Aldrich, Zwijndrecht, The Netherlands). Radiochemical 
purity was determined by Instant Thin Layer Chromatography (ITLC) on silicagel, using 
20 mM sodiumcitrate buffer (pH 5.0) as mobile phase. 
 
SPECT/CT and fluorescence imaging
Imaging with the U-SPECT II scanner (MILabs, Utrecht, The Netherlands) was 
performed 48 hours after injection of the dual-labeled antibody preparations via the 
tail vein. A 1.0 mm diameter multipinhole Ultra High Sensitive (UHS-M) collimator 
tube was used. Mice were anesthetized with a mixture of oxygen, N
2
O and isoflurane 
and placed in a supine position in the scanner. Body temperature was maintained at 
37 °C during the scan. Total scan time was approximately 60 minutes per animal for 
SPECT acquisition and 3 minutes for CT imaging. Images were reconstructed using the 
MILabs software (MILabs, Utrecht, the Netherlands). Immediately after completing of 
image acquisition, mice were euthanized, and placed in supine position in the optical 
scanner after removal of the abdominal skin. Optical images were acquired with the 
IVIS Lumina imaging system (recording time 1-3 min; binning factor medium; emission 
filter ICG; FOV C; excitation filter 745 nm) (Caliper life sciences, Hopkinton, MA, USA). 
 
Processing of the tumor specimens
After dissection, tumor specimens were processed and 10-μm sections were cut. 
Ex vivo autoradiography studies were performed by exposing the sections to 
an imaging plate (Fuji Film BAS-SR 2025; Raytest, Straubenhardt, Germany) for 1 
hour. Images were acquired with a radioluminography laser imager (Fuji Film BAS 
1800 II system; Raytest) and analyzed with Aida Image Analyzer software (Raytest). 
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Sections were subsequently measured with the Odyssey 9120 fluorescence 
imaging system (800 nm channel, 42 μm resolution) (LICOR biosciences, Lincoln, 
NE, USA). CAIX expression was detected by staining with anti-CAIX mouse mAb 
M75, a hybridoma supernatant obtained from the HB-11128 ATCC cell line. 
 
Biodistribution studies
After SPECT and optical image acquisitions, mice were euthanized and tissues 
dissected for ex vivo biodistribution studies. A tumor sample and samples of 
normal tissues (blood, muscle, heart, lung, spleen, pancreas, stomach, duodenum, 
kidney, liver) were dissected, weighed and counted in a γ-counter (1480 Wizard 
3’’, LKB/Wallace, Perkin-Elmer, Boston, MA, USA). Injection standards were also 
counted to correct for radioactive decay. Tissue uptake of the dual-labeled 
antibody was expressed as percentage of the injected dose per gram (%ID/g).
 
Statistical methods
Statistical analyses were performed using IBM SPSS Statistics version 20.0 (Chicago, 
IL, USA) and GraphPad Prism version 5.03 (San Diego, CA, USA). Differences in 
uptake of dual-labeled antibodies determined from the biodistribution studies 
were tested for significance using t-tests. Differences were considered significant at 
p<0.05, two-sided. All values are expressed as mean ± standard deviation (SD). 
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Results
SPECT/CT and optical images acquired 48 hours after injection of 
111In-DTPA-G250-IRDye800CW clearly delineated the i.p. growing CAIX-expressing 
ccRCC lesions. As early as one week after tumor cell inoculation, tumor lesions were 
clearly visualized with both imaging modalities in 3 out of the 4 animals (Figure 1). In 
the animal where SPECT/CT and optical imaging did not indicate the presence of tumor 
lesions, no macroscopic tumor lesions were found during meticulous examination of the 
peritoneal cavity. Although deeper lying lesions (e.g. subhepatic or lesions within the 
mesentery) could not be detected with optical imaging due to the limited penetration 
depth of the emitted light, very good concordance between the SPECT/CT and optical 
images of more superficially located tumors was observed (Figure 1). All abdominal 
tumor lesions detected with optical imaging were subsequently removed. After removal, 
no residual tumor could be detected with optical imaging or macroscopically (Figure 2). 
Some physiologic uptake of the conjugate in the liver was observed. In addition, 
retention of products of catabolism could be detected in the bladder. Excellent 
concordance between autoradiography and fluorescence imaging of the tumor 
sections was observed (Figure 3).
The high and specific accumulation of 111In-DTPA-G250-IRDye800CW in the CAIX-
expressing tumors was confirmed by the biodistribution data (Figure 4). The highest 
tumor uptake of 111In-DTPA-G250-IRDye800CW (58.5 ± 18.7 %ID/g) was observed one 
week after tumor cell inoculation. Mice injected with the isotype-matched irrelevant 
111In-DTPA-NUH-82-IRDye800CW conjugate demonstrated significantly lower tumor 
uptake (5.6 ± 2.3 %ID/g, p =0.008) one week after inoculation. In the course of the 
experiment, tumor and blood levels decreased and liver uptake increased (Figure 
4). Tumor-to-liver ratios steadily decreased from 2.55 after one week to 0.36 5 
weeks after tumor induction, resulting in tumor-to-liver ratios of 2.16, 1.95 and 1.13, 
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Figure 1. SPECT/CT and fluorescence images of mice one week after tumor cell inoculation. Clear visualization 
of an i.p. growing ccRCC tumor lesion was observed 48 hours p.i. of 111In-DTPA-G250-IRDye800CW (A). 
Some physiological uptake of the tracer in the liver and retention of catabolic products in the bladder and 
urine was observed. In the animal receiving dual-labeled NUH-82  (B), a parasplenic lesion was detected 
macroscopically (blue circle), but this lesion was not detected by either imaging modality. 
Figure 2. Preoperative SPECT/CT image (left) and fluorescence image (middle) of a mouse with an 
i.p. growing ccRCC tumor lesion, 48 hours p.i. of the tumor targeting dual-labeled imaging probe 
111In-DTPA-G250-IRDye800CW. The tracer also shows some physiological uptake in the liver. The abdominal 
tumor lesion (arrow) was subsequently removed by fluorescence image-guided surgery (right). After 
resection, no residual tumor was detected with optical imaging or macroscopically.
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after 2, 3 and 4 weeks, respectively and these were significantly higher than at 5 weeks 
after inoculation (p =0.005, p =0.013 and p =0.004, respectively). 
 
Discussion
In this study dual modality imaging and image-guided surgery of tumor lesions with 
the dual-labeled tracer 111In-DTPA-G250-IRDye800CW was tested in a ccRCC model. 
Both SPECT and fluorescence images showed high and specific accumulation of the 
dual-labeled G250 in the CAIX expressing tumor lesions, with very good concordance 
between the two modalities (Figure 1). After the imaged-guided surgery, no residual 
tumor was detected with optical imaging or macroscopically (Figure 2) indicating that 
pre- and intraoperative detection of CAIX-expressing lesions might be feasible with 
this tracer. 
Figure 3. Autoradiography (A) and fluorescence 
(B) images of a tumor section 48 hours 
after injection of 111In-DTPA-G250-IRDye800CW. 
Enhanced uptake of the tracer can be observed 
in a vital tumor region (HE staining, C) with high 
CAIX expression (M75 staining, D). 
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The high and specific accumulation of 111In-DTPA-G250-IRDye800CW in the 
CAIX-expressing tumor lesions was confirmed by the biodistribution studies (Figure 
4). Accumulation of the tracer in the tumor lesions was highly dependent on the total 
tumor load, in concordance previous studies [14, 18]. Especially in the mice with a 
high tumor load (five weeks after tumor cell inoculation), tumor uptake levels were 
significantly lower than tumor uptake levels in animals with lower tumor burden. In the 
course of the experiment, gradually decreasing tumor accumulation along with lower 
blood levels and increasing liver uptake was observed (Figure 4). In addition, tumor-
to-liver ratios decreased dramatically (Figure 4). This could be the result of antibody 
conjugate binding to circulating antigen in the blood [19], which will lead to rapid 
clearance of the antibody-antigen immune complexes via the liver. 
The results of our study indicate that intraoperative detection of primary ccRCC 
tumors and positive resection margins might be feasible in patients. The detection of 
positive resection margins could theoretically either take place intracorporally or by 
ex vivo examination of the surgical specimen during surgery. Moreover, G250-based 
fluorescence imaging can potentially be used for metastasectomy in patients with a 
history of ccRCC. 
An important advantage of the currently used mAb G250 is that it has been 
studied extensively in clinical trials over the years [20-27], indicating that clinical 
translation of this dual-labeled tracer is feasible. In addition, labeling the antibody 
preparation with 111In enables high quality pre-operative whole body SPECT 
imaging, which can be helpful in clinical decision making in these patients [24]. 
Although the results of the present study are promising, several parameters may 
affect the visualization of ccRCC lesions. Firstly, targeting of the antibody and 
thus the intensity of both the radioactive and the fluorescent signal is dependent 
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Figure 4. Biodistribution of the dual-labeled 
antibody 111In-DTPA-G250-IRDye800CW and 
111In-DTPA-NUH-82-IRDye800CW at 48 hours after 
injection in animals at various time points after 
tumor induction demonstrating specific tumor 
targeting. Tissue uptake is expressed as %ID/g. 
Values represent mean ± SD. Note the decreasing 
tumor and blood levels and increasing liver uptake 
over time.
on the degree and extent of CAIX expression. Although CAIX expression in most 
ccRCCs is homogeneous, G250-uptake is quite heterogeneous due to differences 
in perfusion, vascular permeability,  and interstitial fluid pressure [25, 28]. As a 
result, uptake of the G250-based tracer may vary substantially between lesions. 
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Secondly,  the antibody/dye molar substitution ratio is known to heavily affect the 
in vivo characteristics of the antibody conjugate, including biological properties, 
signal-to-background ratio, clearance and biodistribution [29, 30]. Indeed, at higher 
substitution ratios (≥ 3) rapid blood clearance and very high liver uptake was observed 
(data not shown). 
Thirdly, the IVIS Lumina set-up differs from the currently available clinical surgical 
imaging systems. Although the i.p. ccRCC tumors were clearly visualized, we do not 
know whether the sensitivity of the preclinical IVIS Lumina system is comparable to the 
clinical systems. It is therefore unclear whether real-time imaging can be achieved in the 
operating theatre. A phase I clinical trial that will shed more light on the feasibility of pre- 
and intraoperative visualization of ccRCC lesions with 111In-girentuximab-IRDye800CW 
is planned.
Conclusions
In this study, the feasibility of dual-modality imaging with the dual-labeled 
antibody preparation 111In-DTPA-G250-IRDye800CW was evaluated in a model 
with i.p. growing ccRCC xenografts. Both SPECT and fluorescence images clearly 
showed specific accumulation of 111In-DTPA-G250-IRDye800CW in the ccRCC 
tumors, with very good concordance between the two imaging modalities. 
These results indicate that pre- and intraoperative detection of CAIX-expressing 
tumors, positive resection margins and metastases might be feasible with this 
dual-labeled antibody preparation. Clinical studies are warranted to assess 
safety, feasibility, and validity of this imaging approach in ccRCC patients. 
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Abstract
A new approach in the treatment of clear cell renal cell carcinoma (ccRCC) is 
radioimmunotherapy (RIT) using anti-Carbonic Anhydrase IX (CAIX) antibody G250. To 
investigate the potential of RIT with lutetium-177 (177Lu)-labeled G250, we conducted 
a protein dose escalation study and subsequently a RIT study with in mice with 
intraperitoneally growing ccRCC lesions. Mice with intraperitoneal xenografts were 
injected with 1, 3, 10, 30 or 100 μg G250 labeled with 10 MBq indium-111 (111In) to 
determine the optimal protein dose. The optimal protein dose determined with 
imaging and biodistribution studies was used in a subsequent RIT experiment in 
three groups of 10 mice with intraperitoneal SK-RC-52 tumors. One group received 
13 MBq 177Lu-DOTA-G250, a control group received 13 MBq nonspecific 177Lu-MOPC21, 
and the second control group was not treated and received 20 MBq 111In-DOTA-G250. 
The optimal G250 protein dose to target ccRCC in this model was 10 μg G250. 
Treatment with 13 MBq 177Lu-DOTA-G250 was well tolerated and resulted in 
significantly prolonged median survival (139 days), compared to controls (49-53 
days, p = 0.015), indicating that RIT has potential in this metastatic ccRCC model.
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Introduction
The approval of targeted therapies such as tyrosine kinase inhibitors (TKIs) and inhibitors 
of mammalian target of rapamycin has revolutionized the treatment of advanced 
clear cell renal cell carcinoma (ccRCC) during the last decade. Sunitinib, pazopanib, 
temsirolimus, and bevacizumab in combination with interferon-α have improved 
progression-free survival and are now approved as first line treatments for metastatic 
ccRCC [1-5]. Unfortunately, these agents have several disadvantages. First, they are 
associated with sometimes severe side effects, such as diarrhea, hypertension, fatigue 
and hand-foot syndrome [6]. Moreover, treatment with these drugs is not curative, 
implicating chronic treatment. In addition, discontinuation of therapy may lead to 
flare-up of disease activity in some of the patients [7]. Continued treatment despite 
disease progression or a switch to another angiogenesis inhibitor with a relatively 
short interval is therefore necessary. 
The need for a less toxic therapeutic option with good and durable responses led 
to studies targeting the Carbonic Anhydrase IX (CAIX) using monoclonal antibody 
(mAb) G250 (chimeric mAb also known as girentuximab). G250 specifically binds 
to CAIX, which is expressed in approximately 94% of the ccRCC and expression 
in normal tissues is limited [8]. This preferential high expression in ccRCC has been 
used in many preclinical and clinical studies for imaging and therapy of ccRCC  [9]. 
Due to the limited efficacy observed in the first clinical trials using iodine-131 
(131I)-girentuximab, the search for more suitable radionuclides was initiated. A 
preclinical study by Brouwers and collegues revealed superior therapeutic efficacy of 
lutetium-177 (177Lu), yttrium-90, or rhenium-186 labeled girentuximab as compared 
to 131I-labeled girentuximab. As tumor growth in mice with subcutaneous (s.c.) was 
delayed most effectively by the 177Lu-labeled antibody [10], a phase I dose escalation 
trial with 177Lu-girentuximab in patients with advanced ccRCC was initiated. The results 
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of this trial were very promising, as 177Lu-girentuximab RIT was generally well tolerated 
and resulted in disease stabilization in the majority of patients [11]. However, now the 
question arises how to combine RIT with other treatment modalities such as tyrosine 
kinase inhibitors, as we recently found that the uptake of girentuximab is markedly 
reduced during treatment with these agents [12]. To design the optimal treatment 
strategy, additional preclinical studies regarding the sequencing of therapies are of 
utmost importance. 
In preclinical studies to date, tumor growth was induced by subcutaneous injection 
of tumor cells or grafting of harvested xenograft tissue, resulting in a single, 
palpable, visible tumor [10, 13]. Although the growth of subcutaneous tumors can 
be monitored easily with caliper measurements, subcutaneously growing xenografts 
differ substantially from tumor lesions in patients, particularly with respect to 
blood supply and physiology [14, 15]. In this study, we evaluated the potential of 
combined radioimmunodetection and RIT with murine G250 in an intraperitoneal 
ccRCC xenograft model that may more closely mimic human metastatic ccRCC. 
Materials and methods
 
Antibodies
G250 is a murine IgG1 mAb which is directed against the CAIX antigen expressed 
in ccRCC. The G250 antibody was affinity purified on a Protein-A column from 
the supernatant of  G250 hybridoma cell cultures. MOPC21 (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) is a murine IgG1 mAb not directed against 
any known antigen and was used as a negative control in the RIT experiment. 
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Conjugation, radiolabeling and quality control
For the antibody dose escalation study both G250 and MOPC21 were conjugated with 
isothiocyanato-benzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) as described 
previously [10]. 
For biodistribution studies, DTPA-conjugated G250 was incubated with 111In (Covidien 
BV, Petten, The Netherlands) in 0.1 M MES buffer, pH 5.5, at room temperature, under 
strict metal-free conditions for 20 minutes as described previously [16]. The specific 
activity of the antibody preparation  was 1.07 MBq/μg (yield 98%). The protein dose 
was adjusted to 3, 10, 30 or 100 μg by adding unlabeled G250. For single-photon 
emission computed tomography(SPECT)/computed tomography (CT) studies, 
67.2 μg DTPA-conjugated G250 was incubated with 403 MBq 111In. This preparation 
was purified on a PD10 column. The specific activity of 111In-DTPA-G250 used for 
imaging studies was 3.4 MBq/μg (overall yield 19%). Again, the protein dose for the 
different groups was adjusted by adding unlabeled G250. Ten megabecquerels 
of 111In-DTPA-G250 was administered intravenously via the tail vein (0.2 mL). 
For the therapy experiment isothiocyanato-benzyl-1,4,7,10-tetraazacyclododeca-
netetraacetic acid (ITC-DOTA) was used as bifunctional chelator because of 
the slightly better stability with 177Lu [10]. DOTA conjugation was performed 
essentially as described by Lewis et al. [17]. No-carrier-added 177Lu was acquired 
from ITG (Gärching, Germany). For RIT, antibody-DOTA conjugates were 
radiolabeled with 177Lu (G250: 46% yield, MOPC21 53% yield) or with 111In (74% 
yield). The radiochemical purity of the radiolabeled antibody preparations in 
the RIT experiment all exceeded 95%. The specific activity of 177Lu-DOTA-G250, 
177Lu-DOTA-MOPC21 and 111In-DOTA-G250 was 1.3, 1.3 and 1.6 MBq/μg, respectively. 
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Cell culture
Tumor growth was induced by an intraperitoneal injection of 0.2 mL of a suspension of 
3x106 SK-RC-52 cells, a CAIX–expressing human ccRCC cell line [18], resulting in tumor 
nodules (submillimeter to 3 mm in diameter) in the peritoneal cavity after 2 to 4 weeks. 
 
Animals
All experiments were conducted in accordance with the principles laid out by the 
revised Dutch Act on Animal Experimentation (1997) and approved by the institutional 
Animal Welfare Committee of the Radboud University Nijmegen. Animals were 
housed and fed according to the Dutch animal welfare regulations. The experiments 
were performed in female nude BALB/c nu/nu mice (8–10 weeks old) weighing 20 
to 25 g (Janvier, le Genest-Saint-Isle, France). Mice were accustomed to laboratory 
conditions for at least 1 week before experimental use and housed under nonsterile 
standard conditions in filtertopped cages with free access to animal chow and water.
 
Protein dose escalation study 
Twenty-five female athymic BALB/c nu/nu mice were injected with SK-RC-52 cells as 
described above and divided in five groups. Three weeks after inoculation, the mice 
were injected with 3, 10, 30 or 100 μg G250-DTPA labeled with 10 MBq 111In. At the 1 
μg dose level, the protein dose was too low for labeling with activity doses required 
for SPECT imaging. Therefore, the conjugate in this group was labeled with 1 MBq 
only, which is sufficient to determine the biodistribution of the radiolabeled antibody. 
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Imaging with the U-SPECT II scanner (MILabs, Utrecht, The Netherlands) was performed 
in the 3, 10, 30, or 100 mg groups 48 hours postinjection of 111In-DTPA-G250. A 1.0 
mm diameter pinhole collimator tube was used. Mice were anesthetized with a 
mixture of oxygen, N
2
O, and isoflurane and placed in a supine position in the scanner. 
Body temperature was maintained at 38°C during the scan. The total scan time was 
approximately 60 minutes per animal for SPECT acquisition and 3 minutes for CT 
imaging. Images were reconstructed using the MILabs software. Immediately after 
completion of image acquisition, mice were euthanized, and the intraperitoneal 
cavity was inspected meticulously for the presence of intraperitoneal tumor 
depositions. Tumor nodules and tissues were dissected, and their concentration of 
the radiolabel (%ID/g) was determined. If no tumor lesions were detected, animals 
were excluded from the ex vivo biodistribution studies. A tumor sample and 
samples of normal tissues (blood, muscle, heart, lung, spleen, pancreas, stomach, 
duodenum, kidney, liver) were dissected, weighed, and counted in a gamma counter 
(1480 Wizard 3, LKB/Wallace, Perkin-Elmer, Boston, MA). Injection standards were 
also counted to correct for radioactive decay. Tissue uptake of the radiolabeled 
antibody was expressed as a percentage of the injected dose per gram (%ID/g).
RIT experiment
For the RIT experiment, thirty female BALB/c nu/nu mice were injected with SK-RC-52 
cells as described and divided into three groups. Two weeks after tumor cell inoculation, 
mice were injected with 10 μg 13 MBq 177Lu-DOTA-G250 (n=10), 13 MBq 177Lu-DOTA-
MOPC21 (control group, n=10), or 20 MBq 111In-DOTA-G250 (control group, n=10). 
The weight of the mice was measured weekly, and mice were euthanized in case of 
excessive palpable tumor growth, substantial weight loss or other signs of significant 
disease progression, as determined by trained biotechnicians who were blinded for 
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the treatment given to the mice. As in the protein dose escalation study, the presence 
of intraperitoneal tumor depositions was scored macroscopically. Animals were 
excluded from survival analyses if no tumor lesions were detected after inspection of 
the abdomen. SPECT/CT imaging to monitor disease progression was performed with 
3-week intervals as described above. Primary endpoints were overall survival and toxicity. 
 
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics version 20.0 (IBM, 
Armonk, NY) and GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA). 
Differences in uptake of radiolabeled antibodies were tested for significance using 
the nonparametric Kruskal-Wallis test and were considered significant at p < 0.05, 
two-sided. Tumor-to-blood (T/B) ratios were calculated by averaging the T/B ratios of 
the individual animals (tumor uptake (%ID/g) divided by blood activity (%ID/g)). Values 
are expressed as mean ± standard deviation. Median survival differences were tested 
for significance using a Mantel-Cox test and were considered significant at p < 0.05. 
Results
Protein dose escalation study
Mice did not show clinical signs of discomfort 3 weeks after inoculation of the 
SK-RC-52 tumor cells. At that time, the intraperitoneal tumor nodules were not 
palpable. On macroscopic inspection of the opened abdomen, multiple solid tumors 
were found, predominantly located at the subhepatic, -splenic, and -phrenic spaces 
and within the mesentery (Figure 1). The number of tumor lesions per mouse was 
typically more than 10, ranging in diameter from less than a millimeter to 3 millimeter. 
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Eighteen of 25 mice (72%) had macroscopically visible tumors at dissection. Mice 
without macroscopically visible tumor growth were excluded from analyses. 
SPECT/CT imaging showed high mAb uptake in the abdomen of mice at all protein 
dose levels. No clear differences in image quality were observed between the 
different groups. After the animals were sacrificed, all imaged areas coincided with 
intraperitoneal tumors which ranged from 1 to 2 mm, demonstrating preferential 
mAb uptake in the tumors. The biodistribution of 111In-DTPA-G250 was determined 
48 hours post injection (Figure 2). Tumor uptake of the radiolabeled antibody was 
very high at all protein dose levels, with the highest mean uptake observed in the 
10 μg group (54.9 ± 3.5), but the difference between the groups was not significant.
The highest T/B ratio was found in the 1 μg group (14.7 ± 11.6), mainly due to lower blood 
values, but the ratio was not statistically significant different from that of the other groups 
(p = 0.297). Significantly higher liver uptake was observed in the 3 μg group (23.0 ± 9.5) 
Figure 1. Intraperitoneal tumor depositions close to the pancreas and spleen 21 days after tumor cell 
inoculation. Note the extensive neovascularization surrounding the tumors (arrow).
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compared to the 10, 30 and 100 μg dose level groups (p = 0.036). At protein dose levels 
≥10 ug favourable T/B ratios (8.5 ± 3.3, 5.1 ± 1.8 and 4.4 ± 1.1, respectively) and lower 
liver uptake was observed, especially in the 10 μg group (T/B ratio 8.5 ± 3.3). Therefore, 
it was concluded that the optimal G250 dose to target ccRCC in this model was 10 μg. 
 
RIT study 
Twenty-nine of 30 mice (97%) developed visible tumors during the experiment as 
assessed by meticulous macroscopic inspection of the peritoneal cavity. All mice survived 
the treatment and apart from mild transient weight loss (<15%) associated with the 
177Lu-labeled antibody preparations, treatment was generally well tolerated. Three mice 
Figure 2. Biodistribution and specific tumor targeting of escalating doses 111In-DTPA-G250 48 hours after 
injection. Tissue uptake is expressed as %ID/g. Values represent mean ± standard deviation. Note the high 
liver uptake in the 1 and 3 μg groups.
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died during the imaging procedures (injections or anesthesia) and were excluded from 
the analyses. One of these animals did not have macroscopically visible tumor growth.
Survival curves of the three groups are shown in Figure 3. Mice reached the humane 
endpoint when signs of significant disease progression or clinical deterioration 
(mainly severe weight loss) occurred, as judged by blinded biotechnicians. Lesion 
size ranged from <1.0 millimeter to 12 mm. Response to treatment was also 
monitored with 111In-DTPA-G250 SPECT/CT. As shown in Figure 4, progression of 
tumor lesions could easily be monitored in vivo, and when animals were sacrificed 
a close correlation between SPECT images and macroscopic tumors was observed. 
Treatment with 177Lu-DOTA-G250 resulted in significantly prolonged median survival of 
139 days, which is significantly longer than the survival of the mice in both control groups. 
The median survival of the mice that received 177Lu-DOTA-MOPC21 was 49 days and 
Figure 3. Kaplan-Meier survival estimates for the three groups in the RIT experiment. Treatment with 
177Lu-DOTA-G250 resulted in significantly prolonged median survival of 139 days, in comparison to 49 days 
(177Lu-DOTA-MOPC21) and 53 days 111In-DOTA-G250 (Mantel-Cox p = 0.015).
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53 days in the 111In-DOTA-G250 treated group (Mantel-Cox test, p = 0.015). The study 
was terminated after 150 days, being the preset endpoint for assessment of survival.
Figure 4. In vivo SPECT/CT imaging of mice 
with intraperitoneal ccRCC tumors. Rapid 
disease progression occurred in an animal in 
the 111In-DOTA-G250 group, which reached a 
humane endpoint after 5 weeks (A). Another 
animal was treated with 177Lu-DOTA-G250 
immediately after baseline imaging (B). Note 
the presence and progression of a tumor in 
the left side of the abdomen after 3 and 6 
weeks (arrows). The tumor was not detected 
with SPECT/CT after 9 weeks and was not 
found during dissection, and possibly 
regressed due to RIT. 
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Discussion
In this study, the potential of radioimmunodetection and RIT with radiolabeled G250 
in an intraperitoneal ccRCC xenograft model was evaluated. The intraperitoneal model 
with the SK-RC-52 cell line proved reliable and highly reproducible, as substantial tumor 
growth was established in the vast majority of the inoculated mice (approximately in 85%).
Several studies indicate that substantial differences in blood supply and physiology exist 
within different tumor models [14, 15]. In current study, we opted for intraperitoneally 
growing tumor nodules to closer mimic metastatic disease with smaller tumor 
depositions in comparison to subcutaneous xenografts. Drawbacks of intraperitoneal 
tumor growth are that the lesions are not palpable the first weeks after induction, and 
that straightforward visual monitoring of the tumor growth is not possible. This makes 
in vivo imaging techniques indispensable if longitudinal quantification of tumor 
burden is required. 
In the protein dose escalation study to determine the optimal antibody dose for in 
vivo targeting of the intraperitoneal ccRCC xenografts, mice did not show clinical 
signs of discomfort 3 weeks after inoculation of the SK-RC-52 tumor cells, nor 
were the intraperitoneal growing tumors palpable. Despite the small size of the 
intraperitoneal tumors, small depositions of approximately 1 to 2 mm and larger 
were well-visualized with SPECT/CT 48 hours post-injection of 111In-DTPA-G250, 
emphasizing the specific and high accumulation of mAb G250. No clear differences in 
image quality between the different dose levels were observed. Due to the low protein 
and radiation dose administered, it is highly unlikely that multiple 111In-DTPA-G250 
injections used for disease monitoring will have any effect on tumor progression. 
The protein dose escalation experiment demonstrated that optimal T/B ratios and low 
liver uptake levels were reached at a protein dose of 10 μg. Very high liver and low blood 
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levels were observed in the animals with normal tumor load after 3 weeks in the 1 and 3 
μg groups. The mAb G250 biodistribution in the animals without any tumor depositions 
in these low protein dose groups was similar to the 10, 30 and 100 μg groups (data not 
shown). This suggests that the antibody distribution at low protein doses is heavily 
influenced by the presence of tumor. An inverse correlation was observed between blood 
levels and liver uptake at the lower protein doses. This correlation could be the result of 
binding of 111In-DTPA-G250 to circulating antigen in the blood due to antigen shedding 
by the tumor [19], which will lead to rapid clearance of the antibody-antigen immune 
complex via the liver, although we have no formal evidence of circulating antigen. 
An additional advantage of an antibody dose of 10 μg or more is that it is easier to 
label the antibody with higher doses of radioactivity, which are required for RIT. In the 
subsequent RIT study, we found a significantly prolonged median survival in the group 
treated with 177Lu-DOTA-G250. The difference in median survival in this study (139 days) 
and our previous results in a s.c. model (300 days) [10], is likely due to the location of the 
tumor depositions, as the i.p. tumors often result in obstruction of the gastrointestinal 
tract, which subsequently leads to rapid weight loss and clinical deterioration of 
the animals. In both models, 177Lu-DOTA-G250 clearly shows therapeutic potential. 
Recently, several clinical studies report severely hampered antibody targeting 
when radiolabeled antibodies are administered during TKI treatment [12, 20]. To 
successfully combine TKI treatment and RIT in the future, additional preclinical 
studies are warranted to investigate the optimal sequence and timing of both 
treatment modalities. The intraperitoneal ccRCC xenograft model used in current 
study mimics metastatic ccRCC and is therefore suitable for future experiments, for 
instance, to determine for how long antibody targeting to the tumor is reduced after 
cessation of the TKI treatment. Better understanding of underlying mechanisms 
could be an important step in the development of successful RIT strategies for ccRCC.
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Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear 
cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, 
the lack of complete responses, the chronic nature of the treatment, and the side effects 
are clear disadvantages. An interesting new approach in the treatment of clear cell 
RCC (ccRCC) is antibody-mediated therapy with the chimeric anti–Carbonic Anhydrase 
IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials 
become available, the question arises of whether TKI treatment can be combined with 
girentuximab-based therapy. In this study, we assessed the effect of the widely used TKI 
sorafenib on the tumor-targeting potential of indium-111 (111In)-labeled girentuximab. 
Methods
111In-girentuximab imaging was performed on 15 patients suspected of having 
a renal malignancy, with surgery being part of their treatment plan. Of these, 
10 patients were treated in a neoadjuvant setting with sorafenib (400 mg orally 
twice daily). Five patients received treatment during 1 week, and 5 patients 
received treatment during 4 weeks. In both sorafenib-treated groups, baseline 
and posttreatment tumor targeting of 111In-girentuximab were compared. Surgery 
was performed 3 days after the last image acquisition. Five additional patients 
were included as a control group and had only a single 111In-girentuximab injection 
and scintigraphy without any treatment. Distribution of 111In-girentuximab was 
determined scintigraphically ex vivo in a 1-cm lamella of the resected tumorous 
kidney. Expression of CAIX and of the vascular marker CD31 was determined 
immunohistochemically on specimens of both tumor and normal kidney tissue. 
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Results
Treatment with sorafenib resulted in a marked decrease of 111In-girentuximab 
uptake in the tumor in ccRCC patients, especially in the group treated for 4 weeks 
(mean change in both sorafenib-treated groups, -38.4%; range, 19.1% to -79.4%). 
Immunohistochemical analysis showed markedly reduced CD31 expression 
and vessel density in the sorafenib-treated groups but no differences in CAIX 
expression between the sorafenib-treated groups and the nontreated patients. 
Conclusion 
Treatment with sorafenib resulted in a treatment duration–dependent significantly 
decreased uptake of 111In-girentumab in ccRCC lesions. These results indicate that the 
efficacy of antibody-mediated treatment or diagnosis modalities is hampered by TKI 
treatment.
119
The effect of tyrosine kinase inhibitors on girentuximab uptake in ccRCC
Introduction
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of renal cell 
carcinoma (RCC) during the last five years. Sunitinib, sorafenib and pazopanib are now 
standard care in patients with advanced disease [1-3]. Although excellent results for 
progression-free survival have been achieved, there are limitations to the use of TKIs. 
First, these agents have a cytostatic rather than cytotoxic effect, and thus complete 
responses are rarely seen. Second, severe side effects such as hypertension, nausea, 
hand–foot skin reactions, and diarrhea can occur, and sustained low-grade toxicity 
can lead to dose adjustments. Third, the long-term effects of these agents are largely 
unknown [4]. Moreover, TKI treatment is chronic, and cessation of treatment may 
lead to flare-up of the disease, possibly due to rapid neovascularisation [5]. A new 
alternative approach in the treatment of clear cell RCC (ccRCC) is antibody-mediated 
therapy using the chimeric anti-Carbonic Anhydrase IX (CAIX) antibody girentuximab 
(cG250). CAIX is an antigen ubiquitously expressed in ccRCC [6, 7], but expression in 
normal tissues is low or absent [8]. The high and specific expression in ccRCC makes 
CAIX an excellent target  for antibody-mediated therapy. Girentuximab has been 
studied in radioimmunotherapy trials in patients with metastatic disease [9-15] and is 
currently studied in trials in an adjuvant setting (ARISER, or Adjuvant RENCAREX [Wilex 
AG] Immunotherapy Trial to Study Efficacy in Nonmetastasised Renal Cell Carcinoma) 
[16]. Because we recently published the promising results for the most recent therapy 
trial [15], the question arises of whether antibody-mediated treatment can be 
combined with TKI treatment. In this trial, we aimed to determine the effect of the 
widely used TKI sorafenib on tumor targeting of  indium-111 (111In)-labeled chimeric 
anti-CAIX monoclonal antibody girentuximab in pre-operative patients presenting 
with a renal mass suspected of being RCC. To assess the effect of the duration  of 
the treatment, patients were either treated during 1 week or during 4 weeks.
120
Chapter 7
Materials and methods
 
Study design
Fifteen patients with renal masses suspected of being RCC and for whom surgery was 
planned were included in this study. Before inclusion at baseline (day - 14 to day 0), a 
physical examination (including vital signs and weight) was performed, biochemical 
laboratory parameters were assessed, and a resting electrocardiogram was made. The 
study as approved by the institutional review board (CMO Arnhem-Nijmegen). Written 
informed consent was obtained from every patient. This trial is registered on www.
clinicaltrials.gov, number NCT00602862. Two groups of 5 patients were infused with 
111In-labeled girentuximab (100 MBq; 5 mg), and whole-body and SPECT images were 
obtained 7 days later. Imaging was followed by treatment with sorafenib (Nexavar 
[Bayer], 400mg twice a day orally) for 1 week or 4 weeks (Figure 1). All sorafenib treated 
patients underwent a second injection with 111In-girentuximab and imaging 7 days 
after injection. The sorafenib treatment was discontinued on the day of the last scan 
in both groups. Five patients served as a control group and received a single infusion 
of 111In-girentuximab 10 days before nephrectomy and were scanned 7 days later 
but did not receive sorafenib treatment. The study design is summarized in Figure 1.
 
Study drugs
Sorafenib was administered orally in a dosage of 400 mg twice a day. Dose interruptions 
and reductions were allowed when there were adverse events of grade III or higher 
according to the Common Terminology Criteria for Adverse Events, version 3.0 
(National Cancer Institute).
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For scintigraphic imaging, diethylenetriaminepentaacetic acid (DTPA) was 
conjugated to girentuximab (cG250;Wilex AG) at pH 9.5. A 50-fold molar excess 
of isothiocyanato-benzyl- DTPA was used to obtain a molar substitution ratio of 
0.5–2.0. After conjugation, the unconjugated DTPA was removed by extensive 
dialysis against a 0.25 M ammonium acetate buffer, pH 5.4. Aliquots of the 
girentuximab-DTPA solution were placed into sterile vials (5 mg in 1.0 mL) and 
stored at-20°C until use. This procedure has been previously described in more 
detail [14]. After inclusion of a patient, the girentuximab-DTPA conjugate was 
labeled with 100 MBq of 111In (Covidien). The volume of 111In-DTPA-girentuximab 
was adjusted to 10 ml with NaCl 0.9%. Radiochemical purity was determined by 
instant thin-layer chromatography. All preparations used in this study exceeded 95%. 
Figure 1. Study design
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Imaging and quantitative image analysis
On the basis of previous studies, whole-body scans were acquired 7 days after 
injection using a double-head γ camera (E.cam; Siemens Inc.), equipped with 
parallel-hole medium-energy collimators (symmetric 15% window over 172 and 
247 keV) and a scan speed of 4 cm/min [17]. The sorafenib-treated groups were 
injected and scanned twice; the same imaging procedures were used for both scans.
In the group that was treated with sorafenib for 1 week, 111In-girentuximab was 
administered at 11 days before the start of sorafenib treatment and on the day 
that treatment began. Treatment with sorafenib was started 4 days after the first 
111In-girentuximab image was acquired. Each time, scintigraphic imaging was 
performed 7 days post injection of 111In-girentuximab (Figure 1). 
In the group that received 4 weeks of sorafenib, 111In-girentuximab was administered at 
7 days before the start of sorafenib treatment and after 21 days of treatment, each time 
followed by scintigraphy 7 days after injection. The sorafenib treatment was stopped in 
both groups on the day of the last scan, and 3 days later a (partial) tumor nephrectomy 
was performed (Figure 1). 
In the control group, patients were intravenously infused with 111In-girentuximab 
10 days before nephrectomy and scanned 7 days after injection of the radiolabeled 
antibody.
Whole body planar images were analyzed quantitatively, as described by 
Visser et al [18]. Regions of interest were drawn around tumors and normal 
kidney. Targeting was expressed as the percentage injected dose per tissue 
weight (%ID/g), assuming a tissue density of 1.0 g/ml. Tumor volumes 
were determined using Inveon Research Workplace software (Siemens Inc).
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Processing of the surgical specimen
After nephrectomy, a 1-cm-thick slice of the resected tissue containing both tumor and 
normal tissue was scanned on the γ camera, using only a single detector. After imaging, 
the slice was cut into1-cm3 blocks. Tissue blocks were weighed, and radioactivity in 
each sample was determined in a well-type γ counter (1480 Wizard; LKB/Wallace, 
Perkin-Elmer). After quantitative analysis, the tissue blocks were processed for 
immunohistochemical analysis.
 
Immunohistochemical analysis
CAIX expression was detected by staining with anti-CAIX mouse mAb M75, a 
hybridoma supernatant obtained from the HB-11128 ATCC cell line. CD31 staining 
was performed with murine anti-CD31 mAb JC70A (Dako). After staining, expression 
of CAIX and CD31 was scored by 4 independent observers on a scale ranging 
from undetectable (-) to low (±), moderate (+), high (++) and very high (+++). 
 
Statistics
A nonparametric Wilcoxon signed-ranked test was performed to assess the change in 
111In-girentuximab uptake in the tumor before and after sorafenib treatment. A p value 
of less than 0.05 was considered significant.
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Results
Patients
Patient characteristics are summarized in Table 1. Ten patients were treated with 
sorafenib (7 women and 3 men; median age, 62.4 y; range, 50.2–74.4 y). The tumors 
of 9 of these patients were ccRCC as determined by pathology (patients 2, 3, 4, 
5, 7, and 9) or contained a ccRCC component (patients 1, 6, and 8). Patient 1 had a 
poorly differentiated tumor, partly ccRCC and partly rhabdoid RCC; patient 6 a partly 
ccRCC and partly papillary dedifferentiated tumor; and patient 8 a partly ccRCC with 
sarcomatoid dedifferentiated tumor. Patient 10 did not have ccRCC but a tumor of the 
chromophobe subtype.
In the control group (3 women and 2 men; median age, 62.2 y; range, 57.1–69.7 y), 
histopathologic examination revealed RCC in all patients. Of these patients, patient 11, 
13, and 14 had the ccRCC subtype. The surgical specimen of patient 12 showed ccRCC, 
but a part was rhabdoid-dedifferentiated. The specimen of patient 15 revealed a type 
2 papillary RCC (Table 1).
Treatment with sorafenib was generally well tolerated. Reported side effects were 
grade 3 skin toxicity according to the Common Terminology Criteria for Adverse Events 
(version 3; National Cancer Institute) in 2 patients, grade 2 diarrhea in 1 patient, and 
grade 2 stomatitis in 2 patients. No dose reductions or interruptions were necessary.
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Scintigraphy
In all patients with later-proven ccRCC, the renal tumors before neoadjuvant treatment 
were readily visualized with 111In-girentuximab. The results of the quantitative analysis 
are summarized in Table 1. Imaging of the 1-cm-thick slices of the resected tumorous 
tissue, followed by histologic analysis, revealed that 111In-girentuximab accumulated 
in areas of vital tumor tissue whereas normal kidney and necrotic or non–ccRCC parts 
showed much lower uptake (Figure 2). In one patient, the lung metastases as observed 
on CT were also visualized with scintigraphy (patient 8, Figure 3). In this patient, 
the uptake in the largest metastasis decreased by 74.8% after 4 weeks of sorafenib 
treatment. Patients 7 and 9 were diagnosed with bilateral renal masses and had 
girentuximab uptake in both lesions before treatment (patient 9, shown in Figure 4). 
Histologic analysis of the surgical specimens revealed that all these lesions were of the 
clear cell type (Table 1).
The mean 111In-girentuximab uptake in ccRCC renal tumors before sorafenib treatment 
was 0.013 %ID/g (range, 0.002–0.025 %ID/g). After 1 week of sorafenib treatment, 
the mean uptake decreased to 0.008 %ID/g (range, 0.002–0.02 %ID/g), indicating a 
mean change of -14.4% (range, 19.1% to -47.1%, p = 0.225). After 4 weeks of sorafenib 
treatment, the mean uptake decreased to 0.004 %ID/g (range, 0.002–0.01 %ID/g), 
which is equivalent to a mean change of -58.3% (range,-39.9% to -79.4%, p = 0.028) 
based on 6 lesions in 4 patients.
The tumors of all 5 patients who served as controls showed accumulation of 
111In-girentuximab, with a mean uptake of 0.018 %ID/g. Uptake of 111In-girentuximab 
was also found in the papillary RCC in patient 15, albeit relatively low compared with 
the mean baseline uptake in the ccRCC tumors (0.003 %ID/g vs a mean of 0.018 %ID/g).
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Figure 2. Macroscopic view (A) and scintigraphy (B) of 1 cm surgical lamella of patient  5. This patient presented 
with a largely necrotic renal mass with extension in the caval vein. Low uptake corresponds with necrotic 
parts, whereas the highest CAIX expression appears to be located in the caval vein extension.
Figure 3. Anterior planar images of patient 8 with a renal mass and lung metastases at baseline (A) and after 
4 weeks of sorafenib treatment (B). Clear targeting is seen of 111In-girentuximab in the renal mass on the left 
side and lung metastases at baseline (arrows). Decreased targeting is observed after 4 weeks of sorafenib 
treatment. 
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Immunohistochemical analysis
The results of the immunohistochemical analyses of the viable parts of the 
tumors are presented in Table 1. All ccRCC tumor specimens expressed CAIX 
(Table 1). Very low CAIX expression was also found in a vital tumor region of 
the surgical specimen of the papillary subtype from patient 15 (not shown). 
Representative examples of post nephrectomy tumor specimens of each of the 3 
groups are shown in Figure 5. From each tumor, multiple tumor blocks with the 
highest 111In uptake per gram of tissue (as determined in a γ counter) were used. 
High expression of CD31 was found in all the tumors in the control group. As expected, 
sorafenib treatment induced a marked reduction of vessel density, as observed 
Figure 4. Posterior planar images of patient 9 with bilateral renal mass at baseline (A) and after 4 weeks 
sorafenib treatment (B). Clear targeting of 111In-girentuximab is seen in both lesions at baseline (arrows). 
Decreased targeting is observed after 4 weeks of sorafenib treatment. 
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Table 1: Patient Characteristics
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by CD31 immunohistochemistry. This effect was more pronounced in the group 
treated for 4 weeks than in the group that was treated for 1 week, suggesting that 
the decrease in vessel density was related to the duration of the sorafenib treatment.
Discussion
This study confirms previous studies showing that ccRCC lesions can be visualized with 
111In-girentuximab imaging [17, 19]. High and specific uptake was seen in tumor lesions 
in all patients with ccRCC.   Most importantly, we found that accumulation of girentuximab 
in ccRCC lesions is markedly reduced after sorafenib treatment in most patients. 
Figure 5. Immunohistochemical analyses of vital tumor specimens from different groups. Neoadjuvant 
treatment with sorafenib resulted in enhanced necrosis (hematoxylin and eosin) and decreased vessel 
density (CD31) but did not have any effect on CAIX expression. Original magnification 20x.
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The effect of sorafenib on the girentuximab uptake was more pronounced in patients 
that were treated with sorafenib for 4 weeks than in the group treated for 1 week (-58.3% 
vs -14.4%). All ccRCC tumor specimens in the current study were positive for CAIX, 
and we found no decrease in CAIX expression after the TKI treatment, indicating that 
sorafenib treatment did not down-regulate CAIX expression. We did observe decreased 
vessel densities in the sorafenib-treated groups when compared with the untreated 
group, making it highly likely that the reduced vessel density in the treated tumors 
results in poor perfusion and decreased uptake of 111In-girentuximab. The decrease 
in vessel density was most prominent after 4 weeks of treatment (Table 1; Figure 5). 
These results are in concordance with previous work of our group showinga similar 
effect of sorafenib on bevacizumab uptake [20] and with preclinical studies with other 
antibodies [21, 22]. Alternatively, the reduced 111In-girentuximab uptake could also be 
due to vascular normalization after sorafenib treatment [23]. Vascular normalization 
may have led to  decreased vessel permeability, which could also have led to reduced 
accumulation of the antibody in the tumor. We also found CAIX expression in a patient 
presenting with a papillary RCC subtype (patient 15). Although CAIX expression has 
been reported in papillary RCC subtypes, the expression is much lower than in ccRCC, 
in terms of both incidence and level of expression [8, 24]. Strikingly, the CAIX expression 
in this particular patient was found in a vital tumor region within a necrotic part of the 
surgical specimen, suggesting this particular expression pattern is hypoxia driven [25].
The TKI-induced decrease of antibody uptake in the ccRCC lesions has major 
implications for future therapeutic regimens combining both TKIs and antibody-
based treatments (either cold or radiolabeled). The results of the present study 
indicate that antibody-mediated treatment should preferably be given before TKI 
treatment. Alternatively, the antibody could be administered after TKI treatment 
has been stopped. The interval required between TKI cessation and antibody 
treatment still needs to be determined in future studies. In addition, the diagnostic 
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performance of radiolabeled antibodies (immunoPET or immunoSPECT) may similarly 
be affected by TKI treatment. Currently, a clinical trial is ongoing that focuses on 
the potential of 124I-girentuximab immunoPET to detect early treatment response 
to sunitinib [26]. It will be interesting to see whether this study also indicates 
that TKIs interfere with the uptake of girentuximab and whether it is possible 
to evaluate the response to TKI treatment with girentuximab-based imaging.
There are some limitations to our study. First, there was a 3-day interval between the 
discontinuation of the sorafenib treatment and the (partial) nephrectomy. Therefore, 
the immunohistochemical findings may not fully reflect the actual effect caused by 
sorafenib, though significant histologic changes in this short interval are unlikely. 
Second, no biopsies of the renal lesions were taken at baseline, and therefore no 
intrapatient comparison of pre- and posttreatment tissue samples could be performed. 
In addition, vascular density may vary largely within and between RCC tumors. However, 
the CD31 expression in the samples from all patients treated with sorafenib for 4 weeks 
was lower than in the other samples, suggesting that the lower vessel density is a direct 
effect of the treatment. Although the changes in CD31 expression after sorafenib 
treatment were evident (Figure 5), microvessel densities in the treated groups 
could not be reliably quantified. In desmoplastic areas of treated tumors, we often 
observed cytoplasmic CD31 expression in nonendothelial cells. This phenomenon has 
been documented before and has been linked to the phenomenon of vasculogenic 
mimicry [27, 28]. Third, the current trial was not designed to assess the duration of 
the sorafenib induced decreased antibody uptake. It remains to be investigated for 
how long antibody targeting to the tumor remains at lower levels after cessation of 
sorafenib treatment. Data on this subject are limited. There are animal data suggesting 
increased antibody uptake after discontinuation of sunitinib treatment [21, 22], 
presumably due to rapid rebound vascularization. To date, no human data are available 
yet. Enhanced uptake of girentuximab shortly after discontinuation of TKI treatment 
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is an interesting feature for further investigation because it could be an important 
step in the development of successful radioimmunotherapy strategies for ccRCC.
Conclusion
This study confirms that ccRCC lesions can be identified with 111In-girentuximab 
scintigraphy. Moreover, we demonstrated that treatment with sorafenib markedly 
reduces the targeting of 111In-girentuximab in ccRCC lesions, suggesting that 
the effect of antibody-mediated treatment modalities would be profoundly 
hampered when directly combined with TKI treatment. Further research to 
evaluate the duration of this effect after discontinuation of TKI treatment is needed.
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Abstract
Introduction
Despite recent advances in treatment of metastatic clear cell renal cell carcinoma 
(ccRCC), i.e. the development of several angiogenesis inhibitors and mTOR 
inhibitors, the search for alternative treatment modalities that can induce durable 
responses with milder toxicity profiles continues. A phase II radioimmunotherapy 
(RIT) trial with lutetium-177 (177Lu)-girentuximab was initiated based on the 
encouraging results of a phase I to evaluate the efficacy of this RIT approach in 
patients with advanced ccRCC. Results of the first 8 patients treated are reported.
Patients and methods
In this uncontrolled, non-randomized phase II trial, patients with progressive metastatic 
ccRCC who met the inclusion criteria received RIT with 177Lu labeled girentuximab if 
targeting of the antibody was observed after a diagnostic injection with indium-111 
labeled girentuximab. Patients were eligible for another treatment cycle if they 
had at least stable disease (SD) on evaluation after 3 months according to RECIST 
v.1.1 and no prolonged grade 4 hematological toxicity was observed. Retreatment 
was at 75% of the previous activity dose with a maximum of 3 treatment cycles. 
Results
Between August 2011 and August 2013, 8 patients enrolled in the study and received 
at least one infusion with 177Lu-girentuximab. SD after the first RIT was observed in 5 
patients (62.5%), whereas progressive disease (PD) was seen in the other 3 patients. Of 
the 5 patients with SD, 2 patients were not eligible for retreatment due to prolonged 
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hematological toxicity after the first RIT cycle. After the second treatment cycle, 
continued SD was observed in 2 out of 3 patients. The treatment was generally well 
tolerated, but resulted in transient grade 3-4 hematological toxicity in all patients.
Conclusions
RIT with 177Lu-girentuximab resulted in disease stabilization in 5 out of 8 patients 
with progressive ccRCC. Apart from transient myelotoxicity, RIT was well tolerated.
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Introduction
Despite advances in the treatment of metastatic renal cell carcinoma (RCC) with 
antibodies targeting the vascular endothelial growth factor (VEGF), tyrosine kinase 
inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the past 
decade [1-10], there is still an unmet need for improved treatment options of this 
disease. The search for novel systemic treatment strategies with less toxicity and 
significant anti-tumor effect has led to therapeutic regimes using radiolabeled 
antibodies specifically targeting tumor-associated antigens expressed on tumor 
cells. For clear cell RCC (ccRCC), which accounts for approximately 85 percent of the 
malignant renal tumors, the radiolabeled chimeric monoclonal antibody girentuximab, 
is extensively investigated for both radioimmunodetection and radioimmunotherapy 
(RIT) [11-20]. Girentuximab specifically targets carbonic anhydrase IX (CAIX), a tumor-
associated antigen ubiquitously expressed in primary ccRCC and its metastases but not 
found in the normal kidney [21-23]. Because of the specific targeting of girentuximab 
to CAIX-expressing lesions, this antibody is a potent carrier for tumor targeted delivery 
of β-emitting radionuclides [24]. Two independent phase I radioimmunotherapy 
(RIT) trials have been carried out using yttrium-90 (90Y) or lutetium-177 (177Lu) labeled 
girentuximab in patients with metastatic ccRCC [17, 25]. These trials were designed 
to assess the maximum tolerated dose (MTD), dosimetry, pharmacokinetics, and 
incidence of human anti-chimeric antibody (HACA) formation. While the results of 
the 90Y-girentuximab trial are not yet available, 177Lu-girentuximab RIT proved to be 
safe and well tolerable at activity dose levels as high as 2405 MBq/m2. Moreover, 17 of 
23 (74%) patients with advanced ccRCC demonstrated stable disease 3 months after 
the first infusion with 177Lu-girentuximab [17]. Because of these encouraging results, a 
phase II trial at MTD was initiated. Here we report the interim results of this ongoing RIT 
trial in patients with advanced ccRCC. 
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Patients and methods
Adult patients with histopathologically proven metastatic ccRCC with evidence of 
progressive (>15% growth) or new RECIST v.1.1 evaluable lesions, with a maximum 
diameter of 5 centimeters, were eligible for participation. Additional inclusion 
criteria were a Karnofsky performance score  > 70, white blood cell (WBC) count > 
3.5 x 109/l, thrombocyte count >150 x 109/l, hemoglobin > 6 mmol/l, total bilirubin 
≤ 2 x upper limit of normal (ULN), aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT ) ≤ 3 x ULN (≤5 x ULN if liver metastases present), (MDRD > 
40 ml/min and a negative pregnancy test for women of child bearing potential.
Previous treatment with external beam radiation, immunotherapy, VEGF inhibitors 
or mTOR inhibitors was allowed, when more than 4 weeks prior to study. Additional 
exclusion criteria included untreated hypercalcemia, cardiac disease with the 
New York Heart Association classification of III or IV and a life expectancy shorter 
than 4 months. In addition, patients with a history or clinical evidence of central 
nervous system (CNS) metastases were excluded, unless previously treated and 
asymptomatic, had no evidence of active CNS metastases for ≥ 3 months prior to 
enrollment, and had no requirement for steroids or enzyme inducing anticonvulsants 
in the last 14 days. Inclusion and exclusion criteria are listed in more detail in Table 1.
The study was registered on the clinicaltrials.gov website (NCT02002312) 
and was approved by the regional Medical Review Ethics Committee of the 
Region Arnhem-Nijmegen. All subjects provided written informed consent.
Radioimmunotherapy in ccRCC
Inclusion criteria         
- Patients with proven advanced and progressive RCC of the clear cell type
- Presence of evaluable lesions all < 5 cm, according to RECIST v.1.1 
- Karnofsky Performance status: > 70 
- Laboratory values:
  • White blood cells > 3.5 x 109/l
  • Platelet count > 150 x 109/l
  • Hemoglobin > 6 mmol/l 
  • Total bilirubin < 2 x ULN 
  • ASAT, ALAT < 3 x ULN (< 5 x ULN if liver metastases present)
  • MDRD ≥ 40 ml/min
- Negative pregnancy test for women of child¬bearing potential (urine or serum)
- Age over 18 years 
- Written informed consent
Exclusion criteria         
- Known or suspected CNS metastases including leptomeningeal metastases. History or clinical   
 evidence of  CNS metastases (unless they are previously-treated CNS metastases and   
 patients meet all 3 of the following criteria: are asymptomatic, have had no evidence   
 of active CNS metastases for ≥3 months prior to enrollment, and have had no requirement for   
 steroids or enzyme inducing anticonvulsants in the last 14 days)
- Untreated hypercalcemia
- Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors or mTOR   
 inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to   
 prevent pathological fractures is allowed , when unirradiated, evaluable lesions elsewhere are   
 present
- Cardiac disease with New York Heart Association classification of III or IV 
- Patients who are pregnant, nursing or of reproductive potential and are not practicing an   
 effective method of contraception
- Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory   
 abnormalities, which in the judgment of the investigator will significantly affect patients’ clinical  
 status 
 
- Life expectancy shorter than 4 months
RCC = renal cell carcinoma; RECIST = Response Evaluation Criteria in Solid Tumors; ULN = upper limit of normal; ASAT = 
aspartate aminotransferase; ALAT = alanine aminotransferase; MDRD = modification of diet in renal disease, formula to 
estimate Glomerular Filtration Rate; CNS = central nervous system; mTOR = mammalian target of rapamycin.
Table 1. Inclusion and exclusion criteria
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Study design 
The primary endpoint of this study was to determine the therapeutic efficacy of 
177Lu-girentuximab in patients with progressive metastatic ccRCC patients using the 
Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Secondary objectives of this 
study were to assess the progression-free survival (PFS) and overall survival (OS) and 
to explore the toxicity of the 177Lu-girentuximab infusions. PFS was defined as the time 
measured from the day of first administration of 177Lu-girentuximab to first progression 
(either radiological or clinical) or death, whichever occurred first. OS was defined as the 
time from the first injection with 177Lu-girentuximab to the date of death from any cause.
A Simon two-stage minimax design was used to calculate the number of patients 
needed to include. The desirable response rate was set at 0.65, with α = 0.05 and β = 
0.10. Response was defined as at least stable disease (SD) on evaluation after 3 months 
according to RECIST v.1.1. Initially 6 patients were included to evaluate the therapeutic 
efficacy. After interim analysis for efficacy, 8 additional patients will be included in this 
study if a response rate of >0.25  is observed after the first treatment cycle in the first 
6 patients. 
 
Study procedures
Preparation of the radiolabeled antibody was performed as described earlier [17]. In 
brief, girentuximab was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA, Macrocyclics, Dallas, TX, USA) and labeled with either 185 MBq 
indium-111 (111In) (Mallinckrodt Medical, Petten, The Netherlands) for the diagnostic 
infusion, or with 2405 MBq/m2 of 177Lu (ITG, Gärching, Germany) for the therapeutic 
infusion. Radiochemical purity exceeded 95% in all cases as confirmed by instant thin 
layer chromatography.
143
Radioimmunotherapy in ccRCC
After screening, all eligible patients received an infusion with 185 MBq/10 mg 
111In-DOTA-girentuximab to enable diagnostic imaging. Whole body planar and Single-
Photon Emission Computed Tomography (SPECT/CT) images were obtained 2 hours, 
2-4 and 5-7 days after injection to determine targeting of the radiolabeled monoclonal 
antibody. If at least one evaluable metastatic lesion was visualized with 111In-girentuximab 
imaging, 177Lu-DOTA-girentuximab (2405 MBq/m2, 10 mg) was administered 9-10 days 
after infusion of 111In-DOTA-girentuximab. Patients were eligible for a maximum of 
three treatment cycles if they did not show progressive disease (PD) and had no grade 
4 hematological toxicities for more than one week. Additionally, if rapid clearance of the 
antibody from the circulation and high liver, spleen and bone marrow uptake due to 
HACA formation was detected on whole body planar images on day 2-4, patients were 
excluded from further RIT cycles. Retreatment followed 12 weeks after the previous 
therapeutic infusion at 75% of the previous activity dose. Patients were monitored 
for 14 weeks for hematologic toxicity. CT scanning to evaluate response according to 
the RECIST v.1.1 criteria was performed at baseline and 12 weeks after each RIT cycle. 
Results
Interim analysis of the therapeutic efficacy of a single infusion of 177Lu-girentuximab 
at the MTD of the phase I clinical trial [17] in the first 6 patients of this phase II study 
showed disease stabilization in 3 of 6 patients (response rate = 0.5). Because the 
response rate was above the predetermined cut-off of 0.25 and no prolonged grade 
4 hematological toxicity was observed in these patients, recruitment was continued. 
A total of 14 evaluable patients will be included. Currently, data of 8 patients who 
received at least one infusion of 177Lu-girentuximab are available and are reported here.
In total, 9 adult patients with metastatic ccRCC were enrolled between August 2011 
and August 2013. One patient was excluded from the study, because known ccRCC 
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lesions did not show any targeting at diagnostic imaging 6 days post injection of 
111In-girentuximab. Histopathological re-examination of the original surgical specimen 
revealed a non-CAIX expressing ccRCC. In the other 8 patients (4 men and 4 women; 
median age: 71.3 year; range: 56.0–75.1 years) accumulation of 111In-girentuximab was 
observed in at least one of the suspect lesions (Figure 1). Patient characteristics are 
listed in Table 2. Seven out of 8 patients had a favorable prognosis and one patient 
had an intermediate prognosis according to the Memorial Sloan-Kettering Cancer 
Center (MSKCC) prognostic scoring system [26]. Two patients had received prior 
systemic treatment with VEGF-TKIs or Interferon-α (INF-α) and two patients had been 
subjected to local therapies (either metastasectomy or external beam radiotherapy). 
Efficacy
Five out of 8 patients (63%) showed stabilization of progressive disease after the first 
treatment cycle (Table 2). Tumor response of the target lesions after RIT 1 is shown 
in Figure 2. The mean growth rate of the target lesions decreased from 18% to 
10%, although large differences were observed amongst patients. Three out (#1, #4 
and #5) of the 5 patients with SD after RIT 1 were eligible for a second therapeutic 
Figure 1. Diagnostic SPECT/CT 
images of patient #4 during the 
first RIT cycle. Clear targeting 
of 111In-girentuximab was 
observed in multiple lung lesions 
and consequently this patient 
was eligible for infusion with 
177Lu-girentuximab. 
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infusion. Disease progression was observed in patient #1 after the second RIT, whereas 
durable responses were observed in patients #4 and #5. These patients were not 
eligible for a third RIT due to slow recovery of myelotoxicity. Patient #8 showed SD 
after the first RIT, but was not eligible for retreatment because of prolonged grade 4 
myelotoxicity. Patients #2, #3 and #7 showed progression of disease during the first 
RIT cycle. Patient #2 died after a hemorrhagic cerebrovascular accident 12 weeks 
after the first RIT, one week before response evaluation was planned. CT imaging of 
the cerebrum revealed that the hemorrhage was caused by a previously undetected 
cerebral metastases. Because this patient had recovered from hematological toxicity, 
it was concluded that this event was unrelated to the study drug. Patient #3 had 
Figure 2. Tumor growth of the target lesions after RIT 1 per patient and the mean of 8 patients according to 
RECIST criteria v.1.1. 
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rapid progression of liver metastases during the first RIT cycle and was therefore 
excluded for retreatment. In patient #7, CT imaging of chest and abdomen showed 
stabilization of the target lesions, however, a new bone lesion in the right shoulder 
was detected with 111In-girentuximab scintigraphy at the start of the second RIT 
cycle (Figure 3). Conventional radiological studies confirmed this observation and 
the patient was subsequently eligible for additional 177Lu-girentuximab infusions.
For all patients, the available PFS and OS intervals are listed in Table 2. The median PFS 
after the first infusion of 177Lu-girentuximab was 6.9 months. Because the numbers are 
small and follow-up of several patients is ongoing, no additional statistical analyses 
were performed.
Figure 3. 111In-girentuximab imaging at the start of RIT 1 and RIT 2 and MRI image of right shoulder during RIT 
2. Despite stabilization of disease in the chest and abdomen after RIT 1 in patient #7, a new bone lesion in the 
right shoulder detected with 111In-girentuximab scintigraphy at the start of the second RIT cycle indicated 
progressive disease. Magnetic Resonance Imaging (MRI) of the right shoulder confirmed this observation 
and the patient was therefore excluded from the study. 
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Toxicity
All patients experienced grade 3-4 thrombocytopenia in the first RIT cycle, with the 
exception of patient #6 (grade 2). The nadir of the platelet count was at median of 
5 weeks post injection of  177Lu-girentuximab (Figure 4). Generally, patients recovered 
from grade 3 or higher thrombocytopenia in 2-3 weeks. In total, 3 patients developed 
a severe thrombocytopenia requiring at least one thrombocyte infusion. Absolute 
platelet counts after RIT 1 were > 150 x 109/l in all but 1 patient, although none of 
the patients reached their pre-RIT thrombocyte levels. In the 3 patients receiving 
a second therapeutic injection, the hematological toxicity was less severe than in 
the first RIT cycle, however, slow recovery from myelotoxicity precluded a third 
treatment cycle in 2 patients. Transient grade 2-4 leucocytopenia was observed 
in 7 patients, with the nadir at a median of 6 weeks after the therapeutic injection 
(Figure 4). Three patients required hospitalization due to febrile neutropenia. 
Apart from the myelotoxicity, treatment with 177Lu-girentuximab was generally 
well tolerated, as 7 patients experienced only mild (grade 1-2) fatigue and 
nausea. No allergic reactions due to the girentuximab infusions were observed. 
Discussion
Interim analysis of the currently available data from 8 patients indicate that 
177Lu-girentuximab RIT resulted in stabilization of previously progressive disease 
in 5 out of 8 patients with advanced ccRCC. The mean growth rate of the target 
lesions decreased after the first RIT cycle (Figure 2), although the overall results 
are clearly influenced by several outliers. Six additional patients who will receive 
at least one 177Lu-girentuximab infusion will be recruited to complete the study. 
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Figure 4. Hematological toxicity during RIT 1. Thrombo- and leucocyte counts are presented as mean ± 
standard error of the mean (s.e.m.).
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RIT with 177Lu-girentuximab resulted in few side effects, although reversible 
grade 3-4 hematological toxicity was observed in all patients (Table 2), which is in 
concordance with the results of RIT treatment in patients with other solid tumors 
[25, 27].  In the 3 patients treated with two RIT cycles, successive injections with 
177Lu-girentuximab at 75% of the previous activity dose did not result in higher 
toxicity levels. The prevalence of grade 3-4 hematological toxicity seems higher 
than in the patients treated at the same dose level (2405 MBq/m2) in the phase I 
trial. To allow subsequent treatment with TKIs (which can also cause hematological 
toxicity), RIT was discontinued in 4 patients who experienced prolonged thrombo- or 
leucocytopenia. Because of the relatively high incidence of grade 3-4 hematological 
toxicity, the currently used dose of 2405 MBq/m2 may have to be adjusted to allow 
all patients to complete the three treatment cycles in case of disease stabilization. 
The results of the current study are encouraging, however, implementation of 
girentuximab-based RIT into clinical practice is not yet possible. At present, one 
of the biggest challenges is to identify patients who will benefit most from RIT. 
Previous studies indicate that RIT is mainly suitable for treatment of small volume 
disease or possibly as adjuvant treatment in selected cases [13, 28]. Although our 
study was designed to evaluate the efficacy of 177Lu-girentuximab RIT in patients 
with metastatic ccRCC, it would also be worthwhile to test 177Lu-girentuximab RIT 
as adjuvant therapy in the future. In that case, the activity dose of 2405 MBq/m2 
may have to be lowered to prevent severe myelotoxicity in an adjuvant setting. 
Besides optimization of the timing of RIT in the management of ccRCC, personalized 
dosing based on dosimetric analysis of the data acquired with the pre-treatment 
111In-girentuximab imaging is likely to improve 177Lu-girentuximab RIT. Previous 
studies have clearly shown the correlation between red bone marrow dose and 
hematological toxicity, and indicate that diagnostic data can be used to accurately 
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predict absorbed doses and myelotoxicity of girentuximab-mediated RIT [29, 
30]. This approach is of particular interest, as the trade-off between efficacy and 
toxicity can be tailored to the individual patient. In the near future, the Positron 
Emission Tomography (PET) tracer zirconium-89-girentuximab will be evaluated 
in ccRCC patients. Preclinical data indicate superior imaging characteristics 
compared to both the 111In-labeled and the radioiodinated antibody [17, 31], and 
PET will allow more accurate quantification of activity doses in the relevant tissues. 
Usage of this tracer might improve the identification of patients who benefit most 
from 177Lu-girentuximab infusions and will allow patient-tailored dosing of RIT. 
Last but not least, an important step to successfully implement girentuximab-
based RIT is to optimize combinations with other treatment modalities such as 
TKIs, the current standard of care in metastatic ccRCC. As we recently reported, 
treatment with TKIs has a profound effect on the uptake of 111In-girentuximab in 
ccRCC lesions [32]. Data from the latter study indicate that the tumor targeting of 
girentuximab-based RIT is severely hampered if given during TKI treatment and that 
RIT should preferably be given either before TKI treatment or after cessation of the 
TKI treatment. Further studies are warranted to evaluate the duration of this TKI-
induced effect and could help to improve treatment strategies for metastatic ccRCC.
In conclusion, the interim results of the currently available data of this ongoing 
phase II RIT trial with 177Lu-girentuximab are encouraging in terms of clinical 
response in patients with progressive metastatic ccRCC. Apart from transient 
myelotoxicity, the toxicity profile of 177Lu-girentuximab RIT seems to be 
mild. Final analyses of this phase II trial will be performed after inclusion of 
6 additional patients and will hopefully shed more light on the therapeutic 
efficacy and safety of this treatment modality in patients with metastatic ccRCC. 
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General discussion and future perspectives 
This thesis describes several studies regarding the detection and treatment of clear cell 
renal cell carcinoma (ccRCC) with monoclonal antibody G250/girentuximab.
Radioimmunodetection
Detection of ccRCC with radiolabeled girentuximab clearly holds promise for the 
future because of its high sensitivity and specificity in detecting both primary ccRCC 
lesions and disseminated disease. Chapter 3 describes our experience with indium-111 
(111In) labeled girentuximab as a non-invasive diagnostic tool to detect ccRCC. We 
found that the presence of ccRCC is highly likely in case of a positive 111In-girentuximab 
immunoSPECT. However, when no accumulation of the radiolabeled antibody is 
observed in the target lesions, other, non-ccRCC malignancies cannot be ruled out 
due to the current lack of specific tracers for these subtypes. In case of a negative 
111In-girentuximab immunoSPECT in patients presenting with a small renal mass, active 
surveillance or biopsy is warranted to further assess the nature of the suspect lesions. 
In addition to our studies focusing on the diagnostic value of 111In-labeled girentuximab 
in ccRCC, extensive experience has been gathered with Positron Emission Tomography 
(PET) tracer iodine-124 (124I)-girentuximab in other centers [1, 2]. An important 
difference between these two girentuximab conjugates is that 111In is a residualizing 
radiometal that will be retained in the cell after internalization, whereas radioiodinated 
girentuximab is rapidly excreted after internalization, leading to a markedly reduced 
tumor visualization [3, 4]. Compared to 124I-girentuximab, 111In-girentuximab is 
easier to produce as an off-the-shelf agent because it does not require specialized 
equipment or additional purification steps after the labeling procedure. However, 
clear advantages of 124I-girentuximab immunoPET compared to 111In-girentuximab 
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immunoSPECT are the superior spatial resolution and the more rapid image 
acquisition of PET and the more accurate quantitative analysis of the PET images. 
Although it is likely that the use of girentuximab-based imaging will increase in 
the near future, it is yet to be determined whether it also can be used for treatment 
monitoring or the selection of patients. Several clinical trials regarding this topic are 
currently ongoing or planned. One particularly interesting trial that will be initiated 
in the near future aims to use molecular imaging to select patients for the currently 
available treatment modalities for ccRCC. This will potentially allow more effective, 
better tolerated and more cost-effective treatment strategies. Moreover, this trial will 
be using the new PET tracer zirconium-89 (89Zr)-girentuximab. 89Zr is a long-lived PET 
isotope (t½ = 3.27 days) and is a residualizing radiometal that can serve as a surrogate 
to predict the in vivo distribution and tumor targeting of the antibody labeled with 
yttrium-90 or lutetium-177 (177Lu).  Because 89Zr-girentuximab is a residualizing 
PET tracer, it has important advantages over both 111In- and 124I-girentuximab. As 
preclinical data already suggest superior imaging characteristics of 89Zr-girentuximab 
compared to both the 111In [5] and 124I-labeled [6, 7] antibody, it will be very 
interesting to see whether this new tracer indeed represents the best of both worlds. 
 
Optical imaging of ccRCC
In addition to improved detection and (re)staging, patient management can potentially 
be further improved by enhanced intraoperative detection of CAIX-expressing 
lesions with girentuximab-mediated near infrared fluorescence imaging. However, 
tissue penetration of the emitted light is limited, potentially hampering detection 
of lesions. This problem may be overcome by a dual-label strategy using antibodies 
that combine fluorescence imaging with radionuclide detection. Such a combination 
enables enhanced detection of lesions by the radioactive signal, which provides 
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sufficient tissue penetration and allows for real-time optical imaging. The results of the 
preclinical studies described in chapter 4 and 5 unequivocally demonstrate that both 
pre- and intraoperative imaging of ccRCC lesions might be feasible with dual-labeled 
girentuximab. Although the use of interventional molecular imaging techniques may 
very well lead to new surgical treatment paradigms for ccRCC, there are still several 
hurdles to overcome before these techniques can be implemented in the operating 
theatre. Therefore, more studies are warranted to achieve the clinical translation of this 
imaging approach. Currently, a phase I clinical trial with dual-label antibody preparation 
111In-girentuximab-IRDye800CW is in preparation.  The main objective of this trial will 
be to assess the safety and feasibility of dual modality imaging with this dual-labeled 
antibody in patients with a primary renal tumor suspect for ccRCC. If it is indeed 
possible to detect ccRCC lesions with both modalities in the clinical setting, additional 
studies are warranted to evaluate the validity and cost-effectiveness of this approach. 
Prospects in girentuximab-mediated radioimmunotherapy
Apart from the advances in radioimmunodetection, substantial progress has been 
made with girentuximab-based radioimmunotherapy (RIT) strategies in ccRCC in 
the last decade. In chapter 8, the encouraging, preliminary results of the ongoing 
phase II RIT trial indicate that RIT might someday be an important component in the 
treatment of ccRCC. However, before girentuximab-based RIT can be implemented 
in clinical practice, several issues need to be resolved. Although 177Lu-girentuximab 
RIT is generally well tolerated, some patients experience prolonged bone marrow 
suppression, which can result in the need for repeated thrombocyte infusions 
or hospital admission in case of leucopenia. In addition, sustained myelotoxicity 
potentially hampers future treatment with tyrosine kinase inhibitors (TKIs). 
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A logical intervention to avoid prolonged myelotoxicity would be to lower the 
administered activity dose during the three treatment cycles. Although reduction 
of, for instance, 20% would better circumvent bone marrow suppression according 
to previous results [8], this could potentially lead to lower efficacy of the treatment, 
which is clearly undesirable. It is expected that advances in dosimetric analysis will 
contribute to the improvement of patient-specific dosing in RIT, because the trade-
off between efficacy and toxicity can then be better tailored to the individual patient.
Another important challenge is the identification of patients that might benefit 
most from RIT. Previous studies indicate that RIT is mainly suitable for treatment 
of small volume disease or possibly as adjuvant treatment in selected cases [9, 10]. 
Experiences gathered in the ARISER trial that showed that prevention of disease 
recurrence by girentuximab depended on CAIX expression levels [11].  It is highly 
likely that, in future, tumor-specific characteristics such as CAIX expression will be 
used for patient stratification. Although histopathological examination of biopsies or 
surgical specimens currently is the gold standard for treatment decisions, molecular 
imaging may replace these in the future. As mentioned earlier, the ongoing clinical 
trials with 89Zr-girentuximab should provide critical evidence in the upcoming  years. 
Another challenge to successfully implement girentuximab-based RIT in patient 
care is optimizing the combination of this therapeutic modality with the current 
standard of care in metastatic ccRCC, namely treatment with tyrosine kinase inhibitors 
(TKIs). As described in chapter 7, treatment with TKI sorafenib had a profound effect 
on the uptake of 111In-girentuximab in ccRCC lesions. These data indicate that the 
effect of girentuximab-based RIT would be severely hampered if given during TKI 
treatment. As a result, RIT should preferably be given either before TKI treatment 
or after cessation of the TKI treatment. Because of the maximal efficacy of RIT in 
small volume disease [10] and the mild toxicity profile compared to TKI treatment, 
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it would probably be most advantageous to start with RIT prior to TKI treatment in 
case of metastatic ccRCC. Carefully designed clinical trials regarding optimization of 
treatment combinations will hopefully lead to better patient care in the near future.
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Summary
Approximately 2200 new patients are diagnosed with renal cell carcinoma (RCC) in the 
Netherlands each year. Due to the increased use of conventional imaging techniques 
such as ultrasound, Computed Tomography (CT) or Magnetic Resonance Imaging 
(MRI), RCC is found more often in an earlier stage. However, a major drawback of 
conventional radiological imaging techniques is that they cannot reliably distinguish 
benign solid lesions from RCC, which often poses clinicians for a diagnostic dilemma. 
Adequate characterization of these lesions based on imaging is essential to avoid 
invasive biopsies and superfluous surgery, but more importantly to not overlook a 
potentially lethal disease. 
The poor diagnostic performance of conventional radiological imaging techniques has 
led to the search for molecular imaging techniques that target disease-specific features. 
In 1986, the monoclonal antibody (mAb) G250 (the chimeric variant of the mAb was 
later denominated girentuximab) that recognized an antigen abundantly expressed 
on RCC tumor cells was first described. The unknown antigen was later identified as a 
member of the Carbonic Anhydrase family and subsequently denominated Carbonic 
Anhydrase IX (CAIX). The antigen is ubiquitously expressed in clear cell RCC (ccRCC), the 
most predominant subtype of RCC, which accounts for approximately 85% of the cases. 
CAIX is overexpressed in up to 94% of the ccRCC cases and is not expressed in normal 
kidney tissue or renal cysts. This high and specific expression of the antigen allows 
for both antibody-mediated imaging and therapy. A detailed overview of important 
preclinical and clinical studies is summarized in chapter 2. The aim of this thesis was to 
further optimize the detection and treatment of ccRCC using radiolabeled mAb G250/
girentuximab. 
In chapter 3, the use of indium-111 (111In)-labeled girentuximab Single Photon 
Emission Computed Tomography (SPECT) as a diagnostic tool in ccRCC patients is 
evaluated. This chapter describes a series of both patients with primary tumors of 
166
Chapter 10
unknown origin and patients with a history of ccRCC presenting with lesions suspect 
for metastases on follow-up imaging. All malignant ccRCC lesions were visualized 
specifically with 111In-girentuximab SPECT, whereas benign lesions were not. Moreover, 
111In-girentuximab imaging was found to be a helpful, non-invasive tool for clinical 
decision making in patients with a history of ccRCC presenting with lesions suspect for 
metastases, particularly in cases with inconclusive conventional imaging or biopsies.
In addition to preoperative radionuclide imaging, radiotracers are frequently 
used during surgical procedures. By now, sentinel-node procedures have become 
a well-established technology in several tumor types. Although this technique 
may help guide the surgeon to the lymph node of interest, it cannot provide 
a precise delineation of tumor lesions or resection margins. The addition of 
a near infrared (NIR) fluorescent label could help to overcome this limitation. 
Because surgery for ccRCC could potentially benefit from fluorescence imaging 
by facilitating intra-operative detection tumor lesions, mAb girentuximab was 
conjugated with optical dye IRDye800CW and tested in several animal experiments. 
In chapter 4, the feasibility to detect ccRCC tumors with fluorescence imaging using 
G250-IRDye800CW was studied in mice with subcutaneous growing ccRCC xenografts. 
In this study, the antibody was conjugated with IRDye800CW and radioiodinated with 
iodine-125 (125I) to allow SPECT imaging as a reference. Subcutaneous CAIX-
expressing ccRCC xenografts were clearly visualized with fluorescence imaging using 
125I-G250-IRDye800CW and showed good concordance with the SPECT images. Ex 
vivo biodistribution studies confirmed the high and specific targeting of the antibody 
preparation in the ccRCC tumors.
To study the potential of fluorescence imaging of CAIX-expressing tumors 
more extensively, this approach was tested in a more advanced ccRCC model 
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with intraperitoneal (i.p.) growing tumor nodules (chapter 5).  In this study, the 
antibody-dye conjugate was labeled with 111In, to allow microSPECT imaging. Again, 
SPECT and fluorescence images showed clear delineation of the i.p. CAIX-expressing 
ccRCC lesions. Moreover, no residual tumor was detected with fluorescence imaging 
or macroscopically after the imaged-guided surgery, indicating that pre- and 
intraoperative detection of CAIX-expressing lesions might be feasible with dual-label 
G250.
Apart from the diagnostic issues in ccRCC, there is an unmet need for improved 
treatment of advanced disease. Over the last decade, the development of agents 
targeting the vascular endothelial growth factor (VEGF) pathway like bevacizumab (with 
Interferon-α), tyrosine kinase inhibitors (TKIs) sunitinib, pazopanib, axitinib, and 
sorafenib and mammalian target of rapamycin (mTOR) inhibitors like temsirolimus and 
everolimus  have marked a new era in the treatment of metastatic ccRCC. Although 
these targeted therapies have demonstrated good clinical efficacy in terms of 
progression free survival (PFS), treatment with these agents is chronic and side effects 
occur frequently and can be severe. The search for novel systemic treatment strategies 
with less toxicity and significant anti-tumor effect has led to girentuximab-based 
radioimmunotherapy (RIT). Chapter 2 provides an overview of efforts made to develop 
successful RIT strategies for metastatic ccRCC, eventually leading to using lutetium-177 
(177Lu) labeled girentuximab.  
In chapter 6, the potential of of radioimmunodetection and RIT with radiolabeled 
G250 was evaluated in a model with i.p. growing ccRCC xenografts. First, the optimal 
antibody dose was determined in a protein dose escalation study. This antibody dose 
was used in a subsequent RIT study, where the efficacy of a single injection of 177Lu-
G250 was evaluated. Treatment with 177Lu-G250 resulted in significantly improved 
median survival compared to the mice in the control groups, indicating that this RIT 
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was also effective in this model that mimics metastasized ccRCC. The model proved 
reliable and is suitable for further optimizing RIT and combinations of RIT and other 
treatment modalities in the future. 
Besides preclinical studies focusing on optimizing 177Lu-girentuximab RIT, 
177Lu-girentuximab has been used in a  phase I trial. In chapter 8, the preliminary results 
of an ongoing phase II RIT trial with 177Lu-girentuximab are reported. The primary 
endpoint of this study is to determine the efficacy of 177Lu-girentuximab in terms 
of tumor response using the Response Evaluation Criteria In Solid Tumors (RECIST). 
Secondary objectives are to determine the PFS, overall survival, and to evaluate 
treatment’s toxicity. 
Patients with advanced progressive ccRCC are treated with a maximum of three 
consecutive RIT infusions at the predetermined maximum tolerated dose of 2405 
MBq/m2 in the first cycle. If an objective response (defined as at least stable disease) 
is seen after the first treatment cycle, patients are eligible for additional treatment 
cycles at 75% of the activity dose of the previous treatment cycle. To ensure antibody 
accumulation in the metastatic lesions, patients receive a diagnostic infusion with 
111In-girentuximab before the therapeutic infusion with 177Lu-girentuximab at the start 
of each treatment cycle. 
From August 2011 to August 2013, 9 patients enrolled in the study. Because no 
targeting of 111In-girentuximab was observed in one of the patients, a total of 8 
patients with metastatic ccRCC were eligible for treatment with 177Lu-girentuximab. 
Objective responses after one treatment cycle were observed in 5 out of 8 patients. 
Of these five patients, two were not eligible for a second therapeutic injection due 
to prolonged hematological toxicity. Two patients with objective responses after 
one cycle showed a prolonged response after the second 177Lu-girentuximab 
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infusion, while the other patient showed disease progression after 6 months. 
Treatment with 177Lu-girentuximab was generally well tolerated, but resulted in 
transient grade 3-4 thrombocytopenia and leukopenia in all patients. Most patients 
recovered fully within several weeks, but in some patients prolonged bone marrow 
suppression was observed, resulting in exclusion for additional treatment cycles.
As the evidence builds that 177Lu-girentuximab has therapeutic efficacy in the majority 
of patients with advanced ccRCC, the question arises whether this approach can be 
combined with the approved therapeutic agents in ccRCC, more specifically TKIs. 
In chapter 7, the effect of widely used TKI sorafenib on the tumor uptake of mAb 
girentuximab was assessed in patients presenting with a renal mass of unknown origin. 
111In-girentuximab imaging was performed twice in 10 patients scheduled for (partial) 
nephrectomy. In between scans, patients were treated with sorafenib for either 1 or 4 
weeks. Neoadjuvant treatment with sorafenib resulted in a marked decrease of 111In-
girentuximab uptake in the ccRCC lesions in these patients, especially in the group 
treated during 4 weeks. 
The results of this study clearly show that the effect of antibody-mediated treatment 
modalities would be profoundly hampered when given during TKI treatment and 
therefore has major implications for future therapeutic regimens combining both 
treatments.
In summary, the studies described in this thesis show that girentuximab-mediated 
detection has great potential for both pre- and intraoperative diagnosis of ccRCC. 
In addition, current results indicate that 177Lu-girentuximab radioimmunotherapy 
yields clinical benefit in the majority of patients with previously progressive ccRCC, 
although combinations with other treatment modalities should be carefully chosen.
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Samenvatting
Jaarlijks wordt bij ongeveer 2200 patiënten in Nederland nierkanker vastgesteld. 
Gelukkig wordt deze ziekte door het toegenomen gebruik van conventionele 
radiologische technieken zoals echografie, CT en MRI tegenwoordig vaker in een 
vroeger stadium gevonden. 
Een nadeel van bovengenoemde technieken is echter dat zij vaak geen onderscheid 
kunnen maken tussen goedaardige en kwaadaardige tumoren van de nier. Dit 
laatste is echter van groot belang voor de behandelend arts: deze wil voorkomen dat 
patiënten onnodige biopsieën of overbodige operaties ondergaan, maar patiënten 
met een potentieel dodelijke ziekte dienen uiteraard adequaat behandeld te worden.
De zoektocht naar technieken die beter in staat zijn om onderscheid te maken tussen 
goedaardige en kwaadaardige tumoren, hebben geleid tot nieuwe beeldvormende 
technieken die gebruik maken van ziektespecifieke eigenschappen. Midden jaren ’80 
werd een monoklonaal antilichaam gevonden dat zeer specifiek gericht was tegen een 
speciek type nierkanker, het heldercellig niercelcarcinoom (Engels: clear cell renal cell 
carcinoma of ccRCC). Het antilichaam werd in de eerste instantie G250 genoemd en 
later girentuximab. Enkele jaren later werd het eiwit (=antigeen) gevonden waaraan 
G250 bindt. Dit antigeen, Carbonic Anhydrase IX (CAIX) genaamd, bleek in zeer hoge 
mate tot expressie te komen bij ccRCC tumoren, maar niet in normaal nierweefsel of 
niercysten. Daarnaast komt dit antigeen slechts in zeer beperkte mate elders in het 
lichaam voor.
Heldercellige niertumoren vertegenwoordigen ongeveer 85% van alle kwaadaardige 
tumoren van de nier en overexpressie van CAIX wordt gevonden in ongeveer 94% 
van de heldercellige tumoren. Door hoge en specifieke expressie van CAIX in ccRCC 
tumoren, is dit antigeen bij uitstek geschikt voor doelgerichte diagnostiek en 
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therapie met behulp van het G250 antilichaam. In hoofdstuk 2 wordt een uitgebreide 
beschrijving gegeven van de belangrijkste preklinische en klinische studies met G250/
girentuximab tot op heden.
In dit proefschrift is een aantal klinisch relevante vragen met betrekking tot het gebruik 
van G250/girentuximab onderzocht. Allereerst is er gekeken naar de mogelijkheid om 
met radioactief gelabeld girentuximab ccRCC tumoren (preoperatief ) te detecteren. 
Ten tweede is er gezocht naar nieuwe technieken om niertumoren en uitzaaiingen 
van nierkanker te visualiseren met behulp van fluorescentie. Als laatste worden 
de voorlopige resultaten van de nog lopende radioimmunotherapie studie met 
girentuximab en de implementatie van deze nieuwe therapievorm in de kliniek 
besproken. 
Hoofdstuk 3 beschrijft het gebruik van indium-111 (111In)-gelabeld girentuximab 
als diagnostisch hulpmiddel. 111In-girentuximab is een radioactieve tracer die 
gedetecteerd kan worden met een Single Photon Emission Computed Tomography 
(SPECT) camera. Zo kunnen ccRCC tumoren op een niet-invasieve manier in beeld 
worden gebracht. In deze studie werden zowel patiënten met een niertumor van 
onbekende origine, als patiënten met ccRCC in de voorgeschiedenis waarbij er 
op basis van conventionele beeldvorming verdenking is op uitzaaiingen, met 
111In-girentuximab SPECT onderzocht. Alle heldercellige niertumoren werden 
gedetecteerd met de 111In-girentuximab SPECT scan, terwijl goedaardige tumoren 
niet aankleurden. Daarnaast kon bij een groot aantal patiënten met verdenking op 
uitgezaaide nierkanker uitsluitsel gegeven worden over de aard van de afwijkingen.
Naast het gebruik bij verschillende (preoperatieve) nucleaire beeldvormende 
technieken, worden radiotracers veelvuldig ingezet bij schildwachtklierprocedures 
(o.a. bij het melanoom en bij borstkanker). Hoewel de chirurg bij deze procedures 
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naar de eerst-drainerende lymfeklier geleid wordt, is deze techniek niet in staat om 
tumoren te visualiseren of af te bakenen. Door het toevoegen van een fluorescent 
label aan het radioactieve girentuximab, kunnen tumoren of lymfeklieren mogelijk 
beter gedetecteerd worden. Omdat de chirurgische behandeling van ccRCC wellicht 
ook verbeterd zou kunnen worden deze technieken, werden een aantal preklinische 
experimenten uitgevoerd waarbij G250 met zowel een radioactieve als een fluorescente 
stof werd gelabeld.
Hoofdstuk 4 beschrijft experimenten in muizen met subcutane ccRCC tumoren, 
waarbij onderzocht is of de tumoren afgebeeld kunnen worden met fluorescentie 
technieken. In dit experiment werd G250 gelabeld werd met de fluorescerende 
stof IRDye800CW. Daarnaast werd G250 gemarkeerd met radioactief jodium, zodat 
het tevens mogelijk was om de tumoren met een SPECT camera af te beelden. 
De tumoren konden met zowel fluorescentie als met SPECT beeldvorming 
duidelijk afgebeeld worden, waarbij er grote overlap was tussen beide technieken.
Vervolgens werden deze fluorescentie technieken getest in een meer 
geavanceerd diermodel, waarbij de ccRCC tumoren in de buikholte van de 
muizen groeiden (hoofdstuk 5). Wederom werd G250 dubbel gelabeld met 
zowel een radioactieve als een fluorescerende stof. Ook in dit model bleek 
het mogelijk om de tumoren met beide technieken in beeld te brengen. 
Bovendien kon er geen resttumor gedetecteerd worden na verwijdering van de 
tumoren die gevonden waren met behulp van de fluorescentie beeldvorming. 
Beide studies tonen aan dat het mogelijk is om met behulp van doelgerichte 
fluorescentie technieken ccRCC tumoren in beeld te brengen, hetgeen 
mogelijk kan leiden tot gebruik van deze technieken gedurende operaties 
vanwege heldercellige niertumoren of uitzaaiingen van deze ziekte. 
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Naast de beperkingen in de detectie van niertumoren met de huidige beeldvormende 
technieken, is er ook nog steeds een grote behoefte aan nieuwe behandelopties 
voor deze ziekte. Hoewel er de afgelopen jaren goede resultaten zijn geboekt 
met een aantal medicijnen die de aanmaak van nieuwe bloedvaten in de tumor 
remmen, is de behandeling met deze zogenaamde angiogeneseremmers (Grieks: 
angio=bloedvat, genesis=ontstaan) chronisch en helaas niet zonder bijwerkingen. 
Ook op dit gebied zou doelgerichte interventie met G250/girentuximab een rol kunnen 
spelen. Door het antilichaam te labelen met een hoge dosis van een radioactieve stof 
die β-straling uitzendt (bijvoorbeeld met radionucliden als yttrium-90, jodium-131 of 
lutetium-177 (177Lu)) kan de straling specifiek in de ccRCC afgeleverd worden en kunnen 
de tumorcellen gedood worden. Deze therapievorm wordt radioimmunotherapie 
genoemd. 
In hoofdstuk 2 wordt een uitgebreide beschrijving van de belangrijkste 
preklinische en klinische therapie studies met G250/girentuximab gegeven, 
welke uiteindelijk hebben geleid tot studies met 177Lu gelabeled girentuximab. 
Hoofdstuk 6 beschrijft de optimalisatie van 177Lu-G250 radioimmunotherapie 
in een muismodel waarbij de ccRCC tumoren in de buikholte van de muizen 
groeiden. Allereerst werd de optimale antilichaam dosis in dit model bepaald, 
waarna deze dosis werd gebruikt in een vervolg studie waarbij het effect van 
één injectie met 177Lu-G250 werd geëvalueerd. De mediane overleving van 
de muizen behandeld met 177Lu-G250 was significant langer dan de muizen 
in de controle groepen. In de toekomst zouden in dit model ook combinaties 
van radioimmunotherapie en andere therapievormen getest kunnen worden. 
Naast preklinische studies met 177Lu-girentuximab, is radioimmunotherapie ook al in de 
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klinische setting geëvalueerd. In hoofdstuk 8 worden de voorlopige resultaten van een 
nog lopende fase II radioimmunotherapie studie met 177Lu-girentuximab in patiënten 
met gemetastaseerd ccRCC beschreven. Het primaire eindpunt van deze studie is de 
effectiviteit van 177Lu-girentuximab volgens de zogenaamde ‘Response Evaluation 
Criteria In Solid Tumors’. Daarnaast zal de progressievrije overleving, de totale 
overleving en de toxiciteit van deze therapie in deze patiënten worden geëvalueerd.
Patiënten met progressieve, uitgezaaide ccRCC worden behandeld met maximaal 
drie opeenvolgende therapeutische injecties met 177Lu-girentuximab. Tijdens 
de eerste cyclus worden patiënten behandeld met op een dosisniveau van 
2405 MBq/m2. De veiligheid van deze dosis radioactiviteit werd reeds in voorgaande 
studies vastgesteld. Indien de eerste therapeutische injectie effectief is (gedefinieerd 
als afname van de uitzaaiingen of stabiele ziekte na drie maanden), kunnen patiënten 
in aanmerking komen voor  een tweede of derde behandelcyclus. Het dosisniveau van 
deze vervolgcycli is telkens 75% van de voorgaande dosis. Om er zeker van te zijn dat 
het antilichaam daadwerkelijk opgenomen wordt in de uitzaaiingen, krijgen patiënten 
voorafgaand aan de therapeutische injectie altijd eerst een diagnostische injectie met 
111In-girentuximab.
Van augustus 2011 tot augustus 2013 werden negen patiënten geïncludeerd in de 
studie. Na de diagnostische injectie werd er bij één patiënt geen opname van het 
111In-gelabelde girentuximab gedetecteerd in de uitzaaiingen, waarop deze patiënt niet 
in aanmerking kwam voor de therapeutische injectie. De overige acht patiënten werden 
wel behandeld  met 177Lu-girentuximab. Bij vijf van de acht patiënten trad stabilisatie 
van de ziekte op, al konden twee van hen geen tweede injectie krijgen vanwege 
beenmergtoxiciteit. De overige drie patiënten ontvingen een tweede therapeutische 
injectie, hetgeen opnieuw resulteerde in stabilisatie van de ziekte bij twee patiënten.
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De radioimmunotherapie werd over het algemeen zeer goed verdragen, maar 
resulteerde in ernstige, tijdelijke onderdrukking van de beenmergfunctie in vrijwel 
alle patiënten. In enkele gevallen was het herstel van het beenmerg echter dusdanig 
traag dat aanvullende behandeling met 177Lu-girentuximab – mede met het oog op 
eventuele toekomstige behandelingen- niet verantwoord werd geacht. 
Nu er in toenemende mate aanwijzingen gevonden worden dat 177Lu-girentuximab 
radioimmunotherapie therapeutisch effectief kan zijn in patiënten met uitgezaaide 
nierkanker, rijst de vraag of deze therapievorm gecombineerd kan worden met 
de standaard therapie voor uitgezaaide ziekte, oftewel of radioimmunotherapie 
gecombineerd kan worden met behandeling met angiogeneseremmers.
In hoofdstuk 7 wordt het effect van angiogeneseremmers op de opname van het 
antilichaam girentuximab in tumoren beschreven. Om dit te onderzoeken, werden tien 
patiënten die een tumornefrectomie zouden ondergaan, twee keer geïnjecteerd met 
111In-girentuximab en vervolgens gescand. Tussen deze scans werden de patiënten 
gedurende één of vier weken behandeld met de angiogeneseremmer sorafenib. Bij 
een controle groep van vijf patiënten werd alleen een scan gemaakt na toediening van 
111In-girentuximab, zonder behandeling met sorafenib. Na de laatste scan werden de 
patiënten geopereerd en werden de veranderingen op weefselniveau en de opname 
111In-girentuximab in de tumor geanalyseerd. 
Behandeling met sorafenib resulteerde in een significante vermindering van de opname 
111In-girentuximab in de niertumoren, met name in de groep die vier weken behandeld 
was met de angiogeneseremmer. Deze resultaten laten zien dat behandeling met 
radioimmunotherapie negatief beïnvloed wordt door gelijktijdige behandeling met 
angiogeneseremmers.
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De studies beschreven in dit proefschrift dragen bij aan de kennis op het gebied van 
de pre- en intraoperatieve detectie van nierkanker en de behandeling met radioactief 
gelabeld G250/girentuximab. 177Lu-girentuximab radioimmunotherapie lijkt stabilisatie 
van progressieve, uitgezaaide nierkanker te bewerkstelligen in de meeste patiënten, 
hoewel combinaties met andere therapievormen zorgvuldig gekozen dienen te 
worden.
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woensdag- of vrijdagavonden. In een druk leven is het erg fijn om af en toe je zinnen te 
verzetten. Ondanks dat prioriteiten soms wat verschuiven en eenieders agenda steeds 
voller wordt, hoop ik dat we elkaar vaak blijven zien. 
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Laurent, thanks voor het meelezen!
Mart en Shenkie, al jaren zijn we beste vrienden in het Nijmeegse en ik vind het dan 
ook fantastisch dat jullie mijn paranymphen zijn. Over een paar jaar staan we er weer, 
maar dan op jullie feestjes!
Broeders! Altijd aan een half woord genoeg, dus bij deze!
Pap en mam, het is natuurlijk geen nieuws, maar ik wil hier nogmaals benadrukken 
dat ik mezelf gelukkig prijs dat ik jullie mijn ouders mag noemen. Door jullie ben ik 
geworden wat ik nu ben! Bedankt voor alle kansen die jullie me gegeven hebben en 
voor jullie niet aflatende steun en interesse. Het was de afgelopen jaren  ontzettend fijn 
te weten dat er in Ugchelen altijd een kop koffie klaarstaat!
Lieve Christa, dit proefschrift is niet compleet zonder een woord aan jou. Je steun en 
betrokkenheid hebben ertoe geleid dat ik naast mijn opleiding dit boekwerk af heb 
kunnen maken. Ik ben ontzettend gelukkig met ons leven in Nijmegen en verheug 
me al op de komende jaren samen met jou! Nu eerst maar eens op vakantie: naar de 
vuurtoren van de voorkant lijkt me wel wat...
